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I declare that I have written this thesis myself. The study was conceived
following conversations with Dr. M. J. Tidman and Professor J. A. A.
Hunter. Through my contacts with colleagues in general practice, I
identified a suitable community population and chose the method of
sampling, the quality of life questionnaires and devised the costing
proforma.
The data collection was all my own work. A little guidance was given by
Dr. Robin Prescott, Dr. D A Ruta and Dr. A. Y. Finlay in their respective
areas of expertise, but the computing and statistical analysis were
completed without assistance.
The data was collected between March 1993 and April 1994. I analysed the
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Definitions
Construct validity The extent to which a new measure relates to
established measures of severity.




The occurrence of new cases of a disease or condition
within a specified time frame. Lifetime incidence is
the occurrence of new cases at any time previously
The overall occurrence of a disease in a specific
population at a speific point in time. The one-year
period prevalence refers to the occurrence over one
year, i.e. includes all individuals who have a disease
or condition at any time over a one year period. Age
specific prevalence refers to a specific age group.






The extent to which a test or measurement result is
reproducible.
The ability of a test to detect a high proportion of true
cases.
The ability of a test to identify correctly true
negatives.




Atopic dermatitis is a chronic, debilitating skin disease. Children have
occupied the major part of investigators' time, but cross-sectional
community studies, encompassing the whole population, are lacking.
This thesis describes an epidemiological study, based on a general practice
of 9,786, and assesses, at all ages, the prevalence, the economic burden to




Many studies have examined the prevalence of atopic dermatitis in children. In
comparison, little has been written about the prevalence of atopic dermatitis in
infants and adults. Diagnostic criteria suitable for use in community surveys have
only recently become available with the introduction of the U.K. Working Party's
Diagnostic criteria. They are simple and non-invasive and contribute to rigorous
community studies.
Atopic dermatitis causes a considerable economic burden to patients and the health
service. Only one study has examined the economics of atopic dermatitis. This
came from the U.S.A., a country whose health care system bears little resemblance
to our own. The Lothian Atopic Dermatitis Study was designed to quantify the
economic burden of atopic dermatitis and to measure the impact on the quality of
life of patients with this common condition.
The study population was a semi-rural general practice of 9,786. A sampling
scheme was devised to identify as many as possible of those in the practice with
atopic dermatitis. One-year period prevalences were calculated by standard
methods for age groups <2, 2-11, 12-15, 16-24, 25-40, 41+. Expense, estimated
over a 2 month period, was attributed to the patient, health service or society
according to the source. One unpublished quality of life measure was used for
children and two well-validated measures, the Dermatology Life Quality Index and
the Patient Generated Index, were completed by adults.
The one year period prevalences were 9.8% for the under 2's, 8.1% age 2-11, 2.2%
age 12-15, 2.1% age 16-24, 2.0% age 25-40 and 0.2% over 40's. This pattern shows
clearly the sharp decline in the prevalence of atopic dermatitis during teenage and
adult years. The largest source of cost to patients was clothing and laundry, and
the mean annual cost to patients was £153. Treatments accounted for the largest
source of expenditure by the health service giving a mean cost per patient of £97.
There were 58 lost working days and 17 lost school days by all patients as a result
of atopic dermatitis. If these results were extrapolated to the U.K. population they
would represent a total annual expenditure of £172m by patients, £125m by the
health service and £168m by society. This adds up to £465m per annum or a per
capita cost of £7.38 per annum. The quality of life measures reflected the range of
severity of atopic dermatitis in the community. The Dermatology Life Quality Index
was not specific for atopic dermatitis but correlated significantly with the Patient
Generated Index.
Thirty-eight per cent of all atopic dermatitis patients are over 16 years of age. Few
studies of atopic dermatitis in adults exist. Clinical studies are necessary to
characterise adult atopic dermatitis and emphasise the pressure from the heavy
economic burden and impaired life quality.
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1.1 Atopic dermatitis - definition
1.1.1 History
Atopic dermatitis (AD) is a common, debilitating skin condition.
Attempts to discover the earliest clinical description have unearthed
some interesting possibilities. Perhaps the earliest record of a patient with
atopy was the Pharaoh Menes of Memphis who may have succumbed to
anaphylaxis in 2,900 BC (Sehgal & Jain, 1993). Later, the Roman Emperor
Augustus Caesar (born 69AD) had problems that could have been due to
respiratory and skin atopy (Mier, 1975).
Robert Willan constructed a classification of skin diseases (Willan, 1808).
He described two types of prurigo: prurigo mitis in younger people and
prurigo formicans in adults. Both may have been akin to AD. In 1844,
von Hebra noted the flexural distribution of pruritic lesions (Hanifin,
1982), and Brocq and Jaquet, in 1891, introduced the terms localised and
disseminated neurodermatitis, used subsequently to describe AD (Brocq &
Jaquet, 1891). The next milestone was in 1892 when Besnier described
three cases of men who had an itchy skin disease in childhood (Besnier,
1892). He called it 'prurigo diathesique' and in so doing was the first to
distinguish AD from other types of dermatitis. It was henceforth known
as 'prurigo Besnier'.
The term atopy (meaning a-no, top-place, y-ness, or unclassifiable), was
not introduced by Coca and Cooke until 1923 (Coca and Cooke, 1923; Coca
et al, 1931). Atopic skin diseases were more clearly delineated in 1932
(Rost & Marchionini, 1932) and the term 'atopic dermatitis' was used first
by Wise and Sulzberger in 1933 (Wise & Sulzberger, 1933).
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1.1.2 Diagnostic criteria
Firm diagnostic criteria, fundamental in all epidemiological research,
were not elaborated until much later. There is no single marker by which
patients with AD can be identified. Clinicians agree when the signs and
symptoms are characteristic, but mild or atypical disease will give rise to
debate. Rigorous criteria are needed to exclude patients with similar
conditions such as seborrhoeic eczema in infants or discoid eczema in
older patients (Yates et al, 1983). The first diagnostic criteria were
suggested independently by Rajka and Hanifin in 1975 and 1977 (Rajka,
1975; Hanifin, 1977), and in 1980 they collaborated on a set of criteria that
has represented the gold standard until recently (Table 1.1) (Hanifin &
Rajka, 1977). However these cumbersome, invasive and unnecessarily
complicated criteria are unsuitable for community studies. Furthermore,
they have never been fully validated.
Several attempts have been made to examine the predictive value of
Hanifin & Rajka's criteria. Diepgen analysed each separately (Diepgen et
al, 1989) but did not analyse all variables simultaneously to determine
the best independent predictors. For instance 'flexural eczema' and
'itching when sweating' are both associated significantly with AD, but if
all who 'itched when sweating' also have 'flexural eczema', this criterion
would make no contribution to the diagnosis of AD. In other words they
are not independent and should not both be included. This work,
therefore, did not shorten the list of features, nor did the authors
construct a more practical diagnostic model.
Attempts have, however, been made to identify the best predictors of AD.
The signs in a control group were compared with those in a group with
definite AD, and features were identified which were significantly more
common in the patients with AD (Svensson et al, 1985). This study had
two major shortcomings. First, the independence of individual features
was not tested. For instance an association with both 'xerosis' and
'seasonal variation' was highly significant, but if both were present in the
same patients, neither would contribute independently to the diagnosis,
and both should not be included. Had all variables been tested
simultaneously the number of criteria in their model may have been
reduced without affecting diagnostic accuracy. The second criticism arises
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because they did not take the next logical step which would have been to
test the criteria in a separate population at risk to determine their
sensitivity and specificity compared with that of experienced clinicians.
Others have looked at the reliability of Hanifin & Rajka's criteria.
Mevorah et al found that two of the so-called 'minor features', anterior
neck folds and the Dennie-Morgan infraorbital fold, were not significantly
associated with AD (Mevorah et al, 1988). Applied to specific populations,
the criteria have been unreliable in infants (Yates et al, 1983), and in a
Chinese population possibly due to ethnic differences (Kang & Tian, 1987;
Kang & Tian, 1989). Conversely, a study from India found two additional
significant features that were not included in Hanifin and Rajka's criteria:
diffuse scaling of the scalp and infra-auricular fissuring (Kanwar et al,
1991).
Lack of specificity has also been revealed. Many of the minor features
occur in patients with respiratory atopy and so are stigmata of atopy rather
than of AD itself (Przybilla et al, 1991). One minor feature, the infraorbital
fold, is common in allergic contact dermatitis (Uehara, 1981). Its frequent
occurrence may be a result of the lower eyelid being a site of predilection
in AD.
Schultz Larsen & Hanifin devised a scheme using a points system which
depended on the presence or absence of various features (Schultz Larsen
& Hanifin, 1992). Patients fell into three groups: 'definite AD', 'possible
AD' or 'not AD', but their scheme did not elucidate the diagnosis in those
in the intermediate group, some of whom may have AD. For research
purposes a set of criteria was needed that would allow patients to be
classified consistently, and in agreement with experienced clinicians, as
either having AD or not.
A process of validation that achieves a balance between sensitivity and
specificity, is required to establish reliable criteria for use in
epidemiological research. If the validation is based on the same
population from which the criteria are derived, an over-optimistic
separation of cases from controls is produced (Svensson et al, 1985). As
the criteria are designed for use in new populations their validity must
also be tested on different populations, as has been done for other
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dermatological conditions (Tan et al, 1982; International study group for
Behcet's disease, 1990). Williams et al have now described well-validated
diagnostic criteria for AD, summarised in Table 1.2, that are sufficiently
'user-friendly' to be applied to community studies (Williams et al, 1994a,
1994b, 1994c). Although there was a small reduction in sensitivity, they
were found to be significantly more specific than Hanifin and Rajka's
criteria. Furthermore, they take account of the distinctive pattern of AD
in infants and of the inability of young children to give a reliable history.
There are three sets of criteria for three age groups (Appendices 1-3). To
qualify as a case of AD, an individual must have a history of an itchy skin
condition, and satisfy three of the subsequent criteria. These are non¬
invasive and can be applied easily by an interviewer with no medical
training. For the first time community studies can now be carried out,
using an appropriate tool for diagnosing AD.
1.2 Atopic dermatitis: the patient's perspective
AD usually starts in infancy and tends to clear with age (Vickers, 1980). Its
main impact is due to its chronicity, to severe itching and to episodes of
infection that cause pain, weeping and bleeding. There are many triggers,
depicted diagramatically in Figure 1.1, although stress and infection are
the most frequent (Morren et al, 1994).
There is no treatment which can be guaranteed to be effective. Some
exacerbations settle with simple topical measures but others require
intensive treatment in hospital with occlusive dressings and systemic
antibiotics. The diagnosis is not always easy in children aged less than 6
months due to lack of scratching and a similarity to viral exanthemata
and other inflammatory skin conditions (Bonifazi & Meneghini, 1989)
(Figures 1.2-1.5).
The distribution of skin lesions gradually alters from infancy to
childhood. The scalp, face and peri-auricular areas are involved at first,
but clear progressively and the rash settles in the flexures during the first
2 years of life (Aoki et al, 1992), a pattern unique to AD (Bonifazi, 1992). In
later childhood, and early adulthood, pruritus and lichenification are
especially distressing, and the face is often affected again, as well as the
neck and upper trunk.
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1.2.1 The natural history
Too few studies of the natural history of AD have been conducted to
permit accurate statements about prognosis. Two retrospective reviews of
infants, diagnosed as having AD 20 years previously, have given
conflicting rates of resolution. The first found that AD was usually
initially noted at age 4 months, and that only 40% with mild eczema and
29% with severe eczema had cleared completely 20 years later (Roth &
Kierland, 1964). The second study from Liverpool, included 2,000 cases
and found that 87% had cleared by the age of 5, but that in subsequent
years the condition returned in some, leading to an overall clearance rate
of 89% by the age of 20 (Vickers, 1980). However many patients do not
develop AD until their teenage years or adulthood, whereas in others the
condition rectus after 20 years of age and would have been missed by
these studies (Lammintausta et al, 1991). This point has been referred to
but has never been the subject of a long-term follow-up study (Wutrich &
Schudel, 1983).
AD usually begins in infancy (Bonifazi & Meneghini, 1989) but diagnosis
at this age is difficult both because young infants cannot localise the site of
an itch, and because of possible confusion with viral rashes or other
inflammatory skin conditions such as seborrhoeic eczema (Yates et al,
1983). As with most AD research, studies of the age of onset have often
only included children (Queille-Roussel et al, 1985), excluding those who
develop AD later, and thereby falsely reducing the estimated age of onset.
This resulted in the high estimate by Queille-Roussel et al of 91.5% of
cases occurring before age 2. Rajka's estimate of 87% developing before 5
may be more realistic and is in keeping with earlier studies (Rajka, 1975;
Hellerstrom & Lidman, 1956; Nexmand, 1948).
The likelihood of complete clearance occurring in infants with AD is hard
to gauge. Prognostically unfavourable factors include severity, a family
history of AD, associated asthma or hay fever, female sex and early age of
onset (Rystedt, 1985).
AD may have profound psychological implications. Adults with severe
AD can become stigmatised and socially isolated. In an early survey many
patients highlighted skin irritation as the worst aspect of AD: it was
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described by one as "like sitting on a bed of ants or spiders" (Jowett and
Ryan, 1985). Others were principally worried about effects on social and
leisure activities, physical appearance, or by the time spent treating their
condition. Other frequent concerns were the ignorance of others and
difficulties with employment, relationships, anxiety and lack of
confidence.
It seems evident that their resources would be drained by laundry bills, by
purchasing over-the-counter (OTC) preparations and by repeated changes
of clothes soiled by blood or topical treatments, but surprisingly this has
never been evaluated.
1.3 Atopic dermatitis: prevalence data
AD makes up a large part of every dermatologist's workload: 13% of new
referrals and 15% of review patients (Harris et al, 1990). Inevitably, much
effort has been devoted to its complex pathogenesis (Bos et al, 1994). The
cellular interactions in the development of an atopic phenotype in the
genetically predisposed have slowly become clearer (Hunter & Herd, 1994,
Hanifin & Chan, 1995). Progress has also been made in the management
of AD and new powerful treatments have been introduced (Przybilla et al,
1994; de Prost, 1992).
In contrast with other atopic diseases, however, there are few good
population-based epidemiological studies of AD (Fleming & Crombie,
1987). A list of population-based publications offering a frequency for AD
is shown in Tables 1.3-1.5. It is hard to decipher any trend because of the
various measures of frequency and different age groups. Most have
concentrated on schoolchildren because they are accessible and have a
high prevalence of AD. To study infants or adults requires a population
study, with its inherent sampling difficulties. The lack of firm diagnostic
criteria has usually been glossed over and data have been collected from
postal questionnaires, health visitor and GP records, and, rarely,
examination by a dermatologist.
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1.3.1 Trend in prevalence
The prevalences recorded in early studies were low (Table 1.3).
Frequencies often included all atopic diseases, and descriptions of
methodology were inadequate. They are of historical interest only, but
there is now much evidence suggesting that the prevalence of AD is
rising (Taylor et al, 1984; Burr et al, 1989; Sibbald et al, 1990; Ninan &
Russell, 1992; Williams, 1992; Schultz Larsen, 1993). Before accepting this
as fact, variables that could influence the prevalence of AD have to be
taken into account. These include climate and geography (Rajka, 1986),
social class (Taylor et al, 1984; Golding & Peters, 1987) and genetics
(Williams et al, 1995b). For example, Afro-caribbean children in the U.K.
have an increased risk of developing AD when compared with white
children in a similar environment (Williams et al, 1995b). Also, many
studies originate from Scandinavia, and differences in climate and the
genetic pool are likely to invalidate direct comparisons with the U.K.
There are also differences between regions in the U.K.: for example, the
1970 national birth cohort suggested that AD is less common in Scotland
and Wales than in other parts of the U.K. (Golding & Peters, 1987).
The most persuasive evidence of a rising prevalence comes from studies
that have looked at the same population over time. Twin studies are also
an attractive model for diseases with environmental and genetic
components (World Health Organisation, 1965). Environmental
influences, however, cannot exist in isolation. Twin studies from
Denmark have shown an increase in prevalence over a 15-year period but
not over the last 5 years (Schultz Larsen et al, 1986; Schultz Larsen, 1993).
Reports from Aberdeen and Cardiff also showed a rising prevalence over
15 and 25 years respectively (Ninan & Russell, 1992; Burr et al, 1989). But
these studies have all relied on questionnaires answered by parents.
Publicity leading to increased public knowledge, and the realisation that
AD is more common in the upper socio-economic groups, have made AD
more socially acceptable, and even fashionable. Perhaps this fashion has
contributed to an apparently rising prevalence. Furthermore, prior
contact with health visitors may have introduced bias into Taylor's study
(Taylor et al, 1984).
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1.3.2 Recent prevalence data
There are now data on the prevalence of AD in various age ranges. In the
1970 birth cohort group, Taylor et al found a lifetime incidence of 12.2% at
age 5 (Taylor et al, 1984). The study included 12,982 children, born
between 5th and 11th April 1970, and traced in 1975. Interviews were by
local health visitors using a standardised questionnaire, but the details of
this, and the basis on which the diagnosis of AD was made, were not
described.
A study of changing asthma prevalence from 1989 also included data on
AD (Burr et al, 1989). They focused on children at schools in a given
catchment area, in their first year at high school, and within a year of
their 12th birthday. Details given of the criteria used to diagnose AD are
minimal, but, by implication, parental recall of 'eczema ever' was used,
and a lifetime incidence of 15.9% was found. The frequency of AD among
Aberdeen schoolchildren was also estimated as part of a study of asthma
and atopy (Ninan & Russell, 1992). Again, no diagnostic criteria are
given, but they quote a lifetime incidence in children aged 8-13 of 12%.
The latter two might be expected to be higher as older age groups were
examined, and in this respect they are consistent. But memory becomes
less reliable with passing time and lifetime incidences based on parental
recall will be subject to variation even if diagnostic acuracy can be
assumed. Furthermore, the lifetime incidence gives no information
about age-specific rates. How many had only infantile eczema, and how
many were still suffering from active eczema?
This problem can be solved by using one-year age-specific prevalences. In
an English general practice, the one-year period prevalence varied from
14.3% in the age group 3-5, to 10.2% in the group 9-11 (Kay et al, 1994).
This work can be criticised as data were collected retrospectively from
medical records and there was no clear definition of AD.
Despite these consistently high estimates, the pattern has been disrupted
by the finding of a point prevalence of 4.3% in 3-15 year olds in a study
from Finland (Poysa et al, 1991).
Recent data on age groups other than young children are few. One infant
study from New Zealand estimated a lifetime incidence of 20.3% at 3 years
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of age (Fergusson et al, 1981), and another of Norwegian Lapps, quoting
an estimated prevalence in 0-4 year olds of 15% (Falk, 1993). Teenagers
have been equally neglected but appear to be affected less. The prevalence
in 12-16 year olds was 3% in 1980 (Larsson & Liden, 1980). The 20 year old
Lambeth study gives prevalences for adults, but their estimates are so
high as to suggest the inclusion of many diagnoses other than AD under
the banner of 'eczema' (Rea et al, 1976). AD in Danish 'Royal Life Guard'
recruits aged 17-24 was estimated to be 3.3% (Svejgaard et al, 1986). The
source of information for a more recent U.S. survey was government
health statistics (Johnson & Roberts, 1978; Johnson et al, 1984). They
covered all ages from one to 74, but quote a low prevalence for age 6-11 of
1.0%, which is not comparable with European studies. The prevalence at
age 35-44 was 0.06 but rose to 0.18 at age 55-64. The reliability of poorly
controlled national surveys like this one must be questioned.
Differences between populations are also seen in the sex ratio (Table 1.6).
The Scandinavian literature finds a predominance of females; that in the
UK a male predominance - the difference may be genetic or artefactual.
There are, therefore, gaps in the statistics that delineate AD. Without
rigorous research, using consistent methodology, any reports of a rising
prevalence must be open to question. Good community data are needed
including all age groups and not just those presumed to have the highest
prevalence.
1.3.3 Ethnic and Social class differences
The frequency of AD is likely to be influenced by race and socio-economic
group.
Racial differences were first highlighted when the rising West Indian
population of the U.K. was shown to have a higher prevalence of AD
than the native population (Davis et al, 1961). This has been confirmed
in a study comparing black Caribbean children born in the U.K. with
white children: a prevalence of 16.3% was found in black and of 8.7% in
white children (Williams et al, 1995b). Another early survey reported a
higher frequency in Chinese than in white children in Honolulu and San
Francisco (Worth, 1962).
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A hospital study of the Asian population in Leicester initially showed a
prevalence apparently different from the white population, but a more
detailed community study failed to confirm this difference (Sladden et al,
1991; Neame et al, 1995).
One of the earliest reports of a socio-economic gradient in the prevalence
of AD was in a study in Honolulu and San Francisco (Worth, 1962).
Differences between socio-economic groups in the U.K. were also found
in the 1970 British national cohort study (Golding & Peters, 1987; Peters &
Golding 1987). The reasons for this are unclear but may include higher
reporting or better recall in some groups. In a well-conducted study of
data from the national perinatal mortality study these results were
confirmed (Shepherd, 1985; Williams et al, 1994d), with AD significantly
more common in social classes I and II than in lower social classes.
Suggested reasons for the difference include higher educational status
that may have lead to an increased uptake of vaccines or overuse of soaps.
Inheritance and environment are both important determinants of AD.
Individuals from different genetic backgrounds in the same
environment, and from a similar genetic pool in different environments,
can clearly differ in their prevalence of AD.
1,4 Economic aspects
Medical practice in the U.K. is becoming increasingly shackled by
economic constraints. Some understanding of the financial implications
of different diseases is now necessary, particularly for the most common
ones such as AD (Harris et al, 1990).
Two cost-effectiveness studies have shown the benefit of using specific
products to treat acne and psoriasis (Cunliffe et al, 1991; Cork, 1993), but
the economic aspects of AD have received scant attention. Only one
publication in recent years has dealt with the cost of AD (Lapidus et al,
1993). This paper, from the USA, estimated the annual cost of treating
children in that country to be $364m, but this figure was derived from a
health care system unlike that of the United Kingdom. No mention was
made of the cost of AD to sufferers, or to society, and the study was
limited to children.
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The analysis of the economics of AD in the USA (Lapidus, 1993) was
limited for three main reasons: it dealt only with children; treatment in
the community was not included; and costs to the patient were omitted.
Given the limited need for expensive in-patient treatment, it was all the
more surprising that the estimated annual cost of $364 million,
equivalent to $1.42 per head of population, was similar to that of
conditions which more often need in-patient treatment (Table 1.7). For
instance, in 1990 the per capita cost of treating inflammatory bowel
disease in the U.S.A. was estimated at between $1.67 and $2.51, and
respiratory syncytial virus infection in children $1.26 (Hay & Hay, 1992;
Meissner, 1994).
In the U.K., AD clearly causes an enormous social burden. However the
cost of treating it is unknown and this is a notable gap in our knowledge.
Data on the cost of treating various age groups, different social groups and
geographical areas are necessary to raise the profile of AD and spotlight
the financial burden to sufferers.
1.5 Assessment of disability
1.5.1 The place of quality of life assessment in medicine
The issues of cost and quality of life are inextricably linked. All clinicians
have to play a part in the difficult task of allocating scarce resources
within the health services (Lazarus, 1994). To do this properly they need
to know which treatments lead to an improved outcome for their
patients, and which are cost effective (Detsky & Naglie, 1990; Cunliffe et
al, 1991).
Reliable measures of quality of life can help here, by providing an
accurate estimate of the benefits conferred by any individual line of
treatment. These benefits can then be balanced against costs.
We now live in a purchaser/provider era with an economic approach to
setting priorities in the health service. Dermatology services are perhaps
at a disadvantage when competing for resources because they deal mainly
with illnesses that do not threaten life and are therefore seen as less
serious, and of low priority by purchasers of health care. Measures of
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quality of life impairment should be incorporated into these assessments
of priority (Delamothe, 1994).
Disability due to disease is largely ignored in the medical curriculum
(Lancet ed, 1986; Claxton, 1994). Doctors are taught how to take a history,
examine a patient, interpret investigations and initiate medical
management, but teaching on the impact of disease is often missing.
Where quality of life has been measured it is often added as an
afterthought (Bergner, 1989). It is seldom the main variable examined
and in a survey of 100 publications using the term 'quality of life', it was
seldom defined (van Dam et al, 1981), and this remains a contentious
issue (Siegrist & Junge, 1989).
1.5.2 The concept of quality of life
Quality of life has been defined as "the extent to which hopes and
ambitions are matched by experience" and the key aim of medical care
should be to "narrow the gap between a patient's hopes and aspirations
and what actually happens" (Caiman, 1984).
'Quality of life' must be distinguished from health status and functional
status, concepts that can be measured in a tangible way (Bergner, 1989).
Functional status is used for assessing activities of daily living. Two
examples of functional status measurements are the Karnofsky
Performance Status and the New York Heart Association Classification,
which have been used for assessing eligibility for clinical trials (Karnofsky
et al, 1980; New York Heart Association, 1979). They are concise and
specific to one disease. Two others that assess performance of everyday
tasks are the Index of Activities of Daily Living and the Barthel Index
which are not specific to any one condition and can be used to evaluate an
individual's ability to live independently (Katz & Akpom, 1976; Mahoney
& Barthel, 1965).
Health Status measures were developed to improve the care and health
of individuals. They include items relating to physical functioning as
well as measures of emotional status and perceptions of health (Patrick &
Deyo, 1989).
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In contrast, quality of life is intangible. Frequently used measures of
quality of life such as the Sickness Impact Profile (Bergner et al, 1981) and
the SF36 (Ware & Sherbourne, 1992) contain many elements that should
be included in a quality of life assessment (Fitzpatrick et al, 1992), and
these are listed in Table 1.8. Some desirable characteristics for a quality of
life measure have been proposed: that they should rely on the statements
of the patient; that they should not be restricted to one moment in time;
and that different periods of time should be compared (van Dam et al,
1981).
1.5.3 Quality of life in dermatology
Early measurements of disability in dermatology were based on leprosy
(Trautman et al, 1965; Ryan, 1991); then the focus of attention turned to
psoriasis (Stankler, 1981; Ginsburg & Link, 1989; Finlay & Kelly, 1987).
Compensation claims have increased awareness of the measures needed
to assess patients with hand eczema (Meding & Swanbeck, 1990). It is
obvious that a chronic condition like AD must also cause massive
incapacity. 64% of patients with acne, psoriasis or eczema attending
hospital clinics in Oxford, reported that their ability to work was reduced
by their disease (Jowett & Ryan, 1985). The effects of severe skin disease
are different from those of the other medical conditions used to develop
quality of life measures; and the study of life quality in individuals with
AD is still in its infancy.
One attempt has been made to develop a measure specific to AD (Eun &
Finlay, 1990). Fifty-five AD patients, over 20 years old, completed a
questionnaire designed to determine which aspects of their lives were
most affected, and a quality of life questionnaire was then constructed
using their responses. This may have been the basis for a good quality of
life measure but its validity has not been fully proven. Construct validity
was significant only at P<0.05, and reliability and criterion validity were
not tested.
Indeed, few measures of outcome are valid, reliable and responsive to
change, or are practicable for everyday use. The Dermatology Life Quality
Index (DLQI) is a simple practical measurement of quality of life in
clinical practice (Finlay & Khan, 1994). It was established by studying one
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hundred and twenty consecutive patients attending a dermatology out¬
patient department who were asked to identify how their skin disease
affected their lives. From this information, a ten-item questionnaire was
constructed, each question scoring 0-3, with high scores representing a
severely impaired quality of life (Appendix 4). Reliability was evaluated
using the test-retest method which, although it gave a significant
correlation (P<0.001), may have been better tested by alternative methods.
Further work on external validity testing is underway but has not yet
been published.
Patients with AD find that their sleep, work and relationships are all
affected by their disease (Jowett & Ryan, 1985), which can also cause
psychiatric disturbances (Blomquist & Sakki, 1991; Ginsburg et al, 1993;
White et al, 1990). Good qualitative data are needed as a measure of the
degree to which patients' lives are altered as well as outcome measures in
AD that truly capture its impact and relevance to patients.
The Patient Generated Index (PGI) is an approach to quality of life
measurement never previously used for skin conditions (Ruta et al,
1994). It was developed for back pain, and shown to be valid, reliable and
to correlate with measures of severity. The elements of life affected by the
condition are chosen by the individual completing the questionnaire.
Subjects will differ in their living conditions, jobs, hobbies, sports and
social activities, and consequently one disease is capable of affecting life in
a variety of ways. For instance patients with AD will be more affected if
they clean their own house than if they employ a domestic. A nurse is
more likely to be affected than a secretary. The PGI not only illustrates the
disability attributable to different lifestyles but can theoretically be used for
any condition in which quality of life is important. This contrasts starkly
with the DLQI that has 10 rigid questions and can only be used for those
conditions for which it was developed.
1.6 Summary
AD is a chronic, debilitating disease that has the capacity to drain
resources and diminish life quality. Most studies of its prevalence deal
only with children and studies of quality of life deal only with adults and
these usually take place in a hospital population. Most sufferers do not
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attend hospital and are therefore more difficult to contact. To advance
our understanding of AD, researchers must resist the temptation to repeat
examinations of groups that are easily accessed and analysed and turn
their attention to communities and subjects in which our knowledge is
lacking. The financial burden on AD patients' families may be heavy and
as yet has attracted no attention in the literature. This area is of central
importance to sufferers and requires further investigation.
1.7 Aims of the study
The specific aims of the Lothian Atopic Dermatitis Study (LADS) were to
answer the following questions:
1. What is the one-year period prevalence at all ages of AD in the
community?
2. What is the economic burden on AD patients and their families?
3. What is the cost of AD to the health service and society?
4. What is the impact of AD on the quality of life of patients and their
families in a community setting?
5. What is the relative performance of the PGI and DLQI in the
measurement of life quality in a community population?
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Table 1.1
Hanifin and Rajka's diagnostic criteria for atopic dermatitis.
To qualify as a case of atopic dermatitis, an individual must have three or
more basic features and three or more minor features.
Basic features Pruritus
Typical distribution - flexural in adults
- facial and extensor in infants
Chronic/relapsing dermatitis



















Intolerance wool & lipid solvents
Perifollicular accentuation
Food intolerance




The UK Working party's diagnostic criteria.
History of an itchy skin condition (or parental report of scratching or
rubbing in a child) plus 3 or more of following:-
1. Onset before age 2 (not used in child under 4).
2. History of flexural pattern of disease.
3. History of asthma or hay fever (or atopic disease of first degree
relative in children under 4).
4. History of dry skin in the last year
5. Visible eczema in flexures (including cheeks, forehead and outer
aspects of limbs if children under 4).
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Table 1.3
Early community studies reporting the prevalence of atopic disease.
Author (Country) Year Frequency Methods
Jiminez (USA) 1934 11.9 Students with atopic diseases








Questionnaire to parents, school health
cards, health centre records
Point prevalence
Children aged 7-14




1956 3.1 Eczema ever
Health visitor cards
Freeman (USA) 1964 'very low' Prevalence not quoted but < 2.8
8th and 12th grade students






Community studies during period 1970-1982















Questionnaire to parents - history













Screening by questionnaire; follow up by













Health and nutrition examination
survey
Patients seen by 101 dermatologists
Kjellman
(Sweden)
1977 8.3 Age 0-7
Larsson
(Sweden)










1982 9.1 Point prevalence
School age
Examination by school medical officer
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Table 1.5
Recent community studies reporting the prevalence of atopic dermatitis































































1 year period prevalence





















1 year period prevalence
Age 3-11
Interview by general practitioner
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Table 1.6.







Schultz Larsen (1993) 1:1.4
Storm (1988) 1:1.5
Table 1.7.
Annual per capita cost of treating AE
compared with other medical conditions
USA Atopic eczema $1.52




Suggested elements that should be included in a quality of life measure
(Fitzpatrick et al, 1992).
1. Physical function - e.g. mobility, self care.
2. Emotional function - e.g. depression, anxiety.
3. Social function - e.g. intimacy, social support, social contact.
4. Role performance - e.g. work, housework
5. Pain
6. Other symptoms - e.g. fatigue, nausea, disease specific symptoms.
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Figure 1.1
Triggers for Atopic Dermatitis
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Figure 1.2
Infant with infected facial atopic dermatitis.
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Figure 1.3
Loss of eyebrows due to rubbing and scratching in
a teenager with facial atopic dermatitis.
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Figure 1.4
Severe facial atopic dermatitis in an adult.
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Figure 1.5






The study population consisted of the 9786 patients in a semi-rural
general practice in Livingston, West Lothian (Figures 2.1-2.4). Livingston
is one of Scotland's new towns. It was established about 40 years ago as an
overflow from Glasgow and lies 15 miles west of Edinburgh. As a new
town its age distribution differs slightly from the rest of Scotland, with
fewer over 65 years of age and more between 20 and 39 (Table 2.1).
However, the prevalence estimates calculated from this population can be
age-adjusted to fit the Scottish population. The distribution of social class
is close to that of Scotland as a whole, but with slightly fewer in social
classes I and V and more in social class III (Table 2.2) (Livingston
Development Corporation, 1994a); this small diversion from the Scottish
population should have little influence on the results. To adjust for
ethnic differences would be more difficult as no data on the ethnic
families in Livingston, or even Scotland, exist, but ethnic minorities
make up only a small proportion of the community.
2.2 The General Practice
Livingston is served by four general practices, each dealing with a
circumscribed area close to the health centre (Figure 2.5). When patients
move from one area to another they are required to register with their
local health centre; consequently patients live near to the centre at which
they are registered. This arrangement is unusual, but ideal for a
community study in which patients must be contacted at home.
Howden Health Centre (HHC), by virtue of its semi-rural location and its
manageable list size, was chosen for the study. The eight general
practitioners (GPs) have an average list size of just over 1200, which
remains in balance as new patients are automatically registered with the
GP who has the smallest list at that time. List sizes are considerably less
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than the average for Scotland of 1900, because all of the GPs work part-
time in a hospital speciality such as paediatrics or obstetrics and
gynaecology. This also helps to foster a close relationship with the local
hospital, St. John's at Howden, and makes local doctors aware of the need
for good community-based research. This project received the
enthusiastic support of all staff at the HHC, medical and office workers
alike.
The practice is well organised, with good inter-personal communication
and regular staff meetings. A computerised system permits practice




Two aims were to assess the cost to, and life quality of patients with AD.
Sampling, therefore, had to ensure that as many patients with AD as
possible could be identified within the study period of one year. Our
chosen method had four separate stages.
1. Patients coded for any type of eczema on the practice computer were
selected and subsequently examined, together with their families, to
establish their precise diagnosis.
2. Few infants with AD were registered in the diagnostic index, perhaps
because of reluctance to diagnose AD so early in life. Therefore all
families with a child aged under 2 years were also questioned and
examined.
3. The diagnostic index on the practice computer was unlikely to be
comprehensive. To estimate the number of cases of AD not
included in stages 1 or 2, a random cluster sample was chosen, each
cluster being a single family, sampled with probability proportional
to size (Cochran, 1977). Families were contacted by telephone; all
adult family members were interviewed, and anyone with a history
of an itchy skin was examined.
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4. One in six of all families which had denied the presence of an itchy
member at stage 3 were examined to reduce the chance of cases of
AD being omitted.
First contact was through a letter signed by their general practitioner
(Appendix 5). Patients were told that they would be contacted by myself,
but further information was withheld to reduce bias due to prior
knowledge of the study. Two weeks elapsed before patients were
telephoned to arrange an interview at their home or at HHC. Those
without a telephone were visited at home. Interviews were usually
conducted with all family members present.
There were no absolute exclusion criteria, but in the case of recent illness
or bereavement contact was delayed.
2.3.2 Practical aspects
The study period was chosen as one year, in an attempt to eliminate
seasonal variation. Lists of patients registered with each of the eight GPs
were sampled sequentially, in random order. Every 6-7 weeks,
appropriate 'listings' of all patients in the care of a specific GP, and
separate lists of all children under 2, and all patients with a diagnosis of
eczema, were printed. Case records for each GP are filed separately and by
address, so that members of one household are filed together. Individual
notes were counted sequentially from the first address, and, using
random number tables, these individuals and their families were
included in the random sample. Those already on the list of eczema
patients or the list of under 2's were excluded. In this way the likelihood
of a family being chosen depended on its size, thereby achieving sampling
with 'probability proportional to size'. Most AD patients are children.
Because larger families are more likely to include children, the sample
encompassed more of those likely to be affected than would a
straightforward random sample.
Each week one sixth of all eczema patients, and a sixth of all families with
a member aged below 2, registered with one GP, were contacted along
with 6 families selected for the random sample. In 6 weeks, all patients in
the sample of a given GP could be contacted. An unbiased selection of
patients was achieved randomly over a one year period, and included
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some infants born during the period of the study, included in the under 2
category.
2.4 Assessment of prevalence
The population was divided into the following age groups: <2, 2-11, 12-15
16-24, 25-40 and over 40. The younger ranges correspond to those used for
the U.K. Working Party's diagnostic criteria, whereas the older groupings
were chosen empirically.
A diagnosis of AD was assigned to all patients who fulfilled the criteria of
the U.K. Working Party. The protocol was adhered to strictly using the
exact wording of each criterion. At the outset of this study these criteria
had not been published but Dr Hywel Williams provided information on
the most recent developments and the most likely format of the final
version. The criteria we used differed slightly from the final version: the
cut off for family history of atopy, infantile pattern and onset was age 2
rather than age 4. A protocol for the diagnosis of flexural eczema that was
being developed for research assistants, a final form of which has now
been published (Williams et al, 1995a), was followed.
All families with children under 2 years were contacted, and so
prevalence could then be calculated as the proportion of those seen who
were affected. The situation with the older groups was more complicated.
To calculate the prevalence in each age group, individuals sampled from
the eczema families, those from the under 2 families, and those from the
random cluster sample had to be considered separately. The statistics are
outlined below.
2.5 Assessment of cost
AD patients identified as above were all included in an estimate of cost.
Individuals who are the subjects of studies may become more focused on
their skin and as a result may visit their doctor more often or apply their
treatment more assiduously, thus introducing a possible source of bias.
To minimise this effect, the initial visit was kept as short as possible;
attempts by patients to discuss their treatment were avoided with an
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explanation that this might bias the results and that an opportunity for a
prolonged discussion would be given at a second visit. All sources of cost
were recorded on a proforma (Appendix 6), and a yellow plastic bag was
provided, in which to collect treatments used during the study period.
Patients were also given an information sheet explaining the purpose of
the survey (Appendix 7).
Cost was assessed over two months. At a second visit at the end of this
period the proforma was scrutinised and responses were elucidated where
necessary. The cost of OTC items were recorded where possible or the
manufacturer, size and location of purchase were noted and the price
ascertained later. Similarly the cost of clothing and laundry in excess of
normal use was recorded. After discussion with a representative of the
South of Scotland Electricity Board, the cost of depreciation of a washing
machine was estimated as £1.54 per week and the cost per wash of
electricity and soap powder was judged to be £0.13 and £0.20 respectively.
Expenditure could then be apportioned to the patient (eg prescription
charges and over-the-counter preparations), to the health service (eg
drugs, and doctor and nurse time) and to society (lost working days). The
unit cost to the health service of each prescribed item can be calculated by
adding £1.40 onto the basic cost listed in the British National Formulary:
£0.70 dispensing fee and £0.70 for professional registration is charged by
the pharmacist. The cost of doctor and nurse time included their salaries
and the running costs of the hospital or health centre, and were calculated
by standard methods (Hughes, 1991), as was the cost to society of lost
working days which was calculated using quoted estimates of £8.42 per
hour (Robinson, 1993) (Table 2.3). For a visit to hospital, on the basis that
25 patients are seen per consultant session, the cost per patient visit
would be £7.21. The cost of a visit to a GP was calculated to be £9.05 (Table
2.4).
2.6 Assessment of quality of life
Two validated questionnaires were used to assess adults. The first was
the Dermatology Life Quality Index (DLQI) developed by Dr A Finlay
(Finlay & Khan, 1994). It consists of ten questions designed to assess
various skin diseases and has been used to measure quality of life in AD.
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Each question contributes a score of 0-3 ('not at all'=0, 'a little'=l, 'a lot'=2,
'very much'=3), giving totals of from 0 to 30. All questions refer to the
impact of the condition over the previous week. AD varies with seasons
(Morren et al, 1994) and so too may the answers to the questions asked. In
an additional questionnaire the same questions were asked as in the
DLQI, but referring to the previous year. The impact on patients' lives at
all times of year can then be encompassed.
The second questionnaire was the PGI (Ruta et al, 1994) which is
completed in three stages (Appendix 8). These are illustrated in Table 2.5.
which demonstrates an example of a 32 year old woman with AD. First,
patients identify the five areas or activities most influenced by their
disease: for instance work, socialising, swimming, housework and sleep
are nominated in the example. Second, each of these areas is given a
score of from 0-100. The lower the score the greater the impairment of
quality of life: in the example 'sleep', is judged to be most profoundly
affected by AD and is given the lowest score of 10. A sixth line is provided
for areas or activities other than those already mentioned, which may or
may not be related to the subject's skin disease. Finally the patient is
given 60 points 'to spend', with most points being given to those areas
they most want to improve: sleep and work were the areas to which the
subject in our example attached most importance. From this information
an overall score of from 0-100 is calculated, by weighting the scores at the
second stage of the PGI according to the priorities assigned at the third
stage.
Although an activity such as 'swimming' may be considerably impaired,
it may not be an area that would be a priority to improve because it can be
bypassed easily. It does not, therefore contribute to the final tally. The
resulting score represents the extent to which reality falls short of
expectation for those areas of life in which they would most value
improvement. In contrast to the DLQI, poor life quality is indicated by
low PGI scores. This questionnaire was designed for adults suffering from
a medical condition, but was also given to parents in this study to assess
the impact on their lives of their children's disease.
Any community study of AD will include many children. Measurement
of life quality in the young is at an early stage. Few measures exist or are
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even being developed. The quality of life questionnaire used here for
children aged 5-15 is currently being developed (Appendix 9). It consists
of three parts. Section A asks patients about their own disease, Section B
asks a parent about their childs' disease, and Section C is an assessment by
one parent of the impact of the childs' disease on the family. The scoring
system is similar to that of the DLQI: each question scores 0-3 (or 0-2 in
question 9) resulting in a maximum possible score of 26 for Section A and
27 for Section B. The maximum for Section C is 39, but this is only
attainable if the patient has brothers and sisters because questions 4, 9a
and 9c ask about sibling relationships. It is therefore imperfect but was
the only questionnaire for children available at the start of this study.
2.6.1 Statistical analysis and validation
Descriptive statistics of the DLQI and PGI were computed individually.
Any new measure of quality of life must be tested to show that it does
genuinely measure changes in the quality of life for individuals in their
particular situation. This is validity and the concept has been refined by
research workers in public health medicine. A rigorous definition is that
'validity is the extent to which a questionnaire measures what is
intended' (Streiner & Norman, 1990). Two aspects of validity were tested
in this study: criterion validity and construct validity. Criterion validity
is the extent to which a new measure correlates with established
measures; whereas construct validity is the extent to which a new
measure relates to specified variables that reflect severity in accordance
with established assessments of severity.
To assess criterion validity, the correlations between the PGI and DLQI,
and between the PGI and individual questions of the DLQI, were
calculated (Armitage & Berry, 1987). As this was a community study
scores in the individual DLQI questions were likely to be low, and those
who scored 0 in each question may form a group distinct from those who
scored 1 or more. Hence, the mean PGI scores of those who scored 0 were
compared, using a t-test, with the scores of those who scored 1-3 in each
item of the DLQI.
The results of the cost evaluation, described in Chapter 4, were used to
test construct validity, by correlating cost and quality of life. It was
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postulated that patients with a poor quality of life measured by the PGI
and DLQI, incur high total costs, health service costs and patient costs.
Although personal costs may in some part be dictated by income, health
service costs, other than prescription costs are more likely to correlate
with severity.
The idea that the open-ended nature of the PGI might confer greater
validity as a quality of life measure in AD, over and above the DLQI, was
tested by the hypothesis that patients would include a broader range of
affected areas in their responses to the PGI than those included in the
DLQI. As a further test of construct validity, patients were divided into 2
groups: group 1 consisted of those who mentioned in the PGI only areas
that are part of the DLQI; and group 2 contained those who mentioned in
the PGI areas outwith the DLQI. If both these groups yield a significant
correlation between the PGI and the DLQI then there is evidence that the
areas outwith the DLQI are also valid for the measurement of quality of
life in AD.
2.7 Hospital assessment
This study was primarily of AD in the community, and only a few of the
patients had severe disease. To compare the cost to, and quality of life of,
more severely affected patients, a cohort attending the Royal Infirmary of
Edinburgh for dressings or admitted to the ward there, was appraised in a
similar way. All patients with AD admitted for in-patient treatment or
accepted for daily dressings, during four two-week periods evenly spaced
throughout the study, were invited to participate.
They were first seen at the time of their admission to the daily dressings
service or to the ward. When the 2 month interview was carried out, all
treatments used in hospital and at home were recorded. Costs were
calculated in a way similar to that for patients in the community, but
included the cost of nurse time and in-patient treatment where
appropriate. Quality of life questionnaires were identical to those used in
the community part of the study.
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2.8 Statistics
Data were coded, loaded onto computer and analysed using the statistical
package SPSS-PC. Calculations of prevalence were carried out by hand,
using standard methods for cluster samples with probability proportional
to size (Cochran, 1977).
2.8.1 Statistics for the under 2 group
There were very few families with more than one child aged less than 2
which allowed this group to be analysed using the normal approximation
to the binomial distribution. If
p = proportion affected
q = l-p
n = sample size
Then the standard error of the estimate of the proportion affected is
2.8.2 Statistics for the older age groups
Each sampling group was considered separately. For each age group the






where M 0 = total number in the population
n=number of families in sample
^proportion of family i who are affected
Y = yM0
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The total estimated number is calculated by adding together the estimates
of Y in all three sampling groups and the variance of this total is the sum
of the separate variances. The prevalence is calculated as a percentage of
the total number in that age group and the variance of the prevalence is
calcuated from the variance of the total estimated number, i.e.
Prevalence = Ly /In x100%
where N = total number in that group
Variance of prevalence = (LVariance x 100%) / ZN
Age groups can be combined by adding the numbers and variances to
estimate, for example, the prevalence for those over 16.
The sex ratios were calculated by considering the sexes separately and
calculating the prevalence in the same way within each age group. The
sex ratios were calculated from these prevalences.
2.8.3 Statistics for the costing section
The Chi square statistic was used for comparing the proportion of those
aged under 16 with those aged over 16, who had no expenditure.
Mean annual costs were computed by multiplying the 2 monthly costs by
6, which gives an unbiased representation of the total costs over one year.
Extrapolation of costs and lost working days were calculated on the basis
that those with AD who had not been identified had expenditure similar
to those identified in the random sample. In other words it was assumed
that those not captured by our sampling method would be represented in
terms of economic burden by those in the random sample. The per capita
cost assumed a U.K. population of 58,191,230.
2.8.4 Statistics for the quality of life section
The DLQI asking about life quality over the previous 2 weeks and 1 year
were compared using the paired Wilcoxon two sample test, and the scores
of the Children's questionnaire were compared using the Wilcoxon




Before data collection started a pilot study was carried out at Dedridge
Health Centre, a general practice neighbouring HHC in Livingston. It
proved suitable because of its similarity to HHC in terms of population
and organisation. Forty patients were seen in one month to establish the
methodology.
Initially the intention was to see all patients who had been prescribed
topical steroids as well as those with a diagnosis of eczema, but the size of
such a sample proved to be unmanageable. As a consequence, the
numbers included in the random sample were increased.
The design of the study was intended to keep bias to a minimum. The
possibility of being contacted before a visit from the investigator might
change patients' responses. To avoid this, patients were contacted by
telephone if possible, or failing this, by a visit. Predictably, a stranger
telephoning or visiting without warning sometimes met with suspicion
or even aggression. Therefore, about 2 weeks prior to the proposed visit,
all households in the main protocol were sent a letter on headed
notepaper, signed by their GP (a copy of which is shown in appendix 5). It
gave limited information about the study. This method also allowed GPs
to screen out families they thought were unsuitable because of illness or
bereavement.
Otherwise the protocol was considered sound and yielded no unexpected




Age distribution of Livingston compared with that of Scotland (% age)






Social class distribution in Livingston compared with the rest of Scotland
Social class Livingston Scotland
1. Professional 3.3 4.5
2. Managerial/technical 21.1 25.2
3. Skilled 47.6 43.3
4. Partly skilled 18.3 15.9
5. Unskilled 6.8 7.7
39
Table 2.3.
Details of calculations of cost of consultation with hospital consultant
Costs listed are based on two consultants working in the same session.









Rait and rates £7.41
Consultants' salaries £162.80
Nurses, aux, records etc £146.00
Total £361.54
Table 2.4.
Details of calculation of cost of GP consultation
Source Charge per quarter Charge per patient
Gross charge £13,769
Admin & clerical £21,756.36
GP salary £53,600 £5.15
Total £89,12536 £9.05
Assuming each GP sees 100 patients per week the cost of a consultation per patient is £9.05.





Activity Score Points Total Score
Work 20 x 20 / 60 = 6.7
Socialising 20 x 10/60 = 3.3
Swimming 30
Housework 20x 10/60= 3.3
Sleep Xo 20 / 60= 3.3




Livingston, situated west of Edinburgh
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Figure 2.2 & 2.3
Housing in the new town of Livingston
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Figure 2.4




Map of Livingston. The area served by Howden
Health Centre is outlined in black
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Chapter 3
Prevalence of Atopic Dermatitis
in the Community.
3.1 Methods in practice
The identification and collection of patient details took one full year, and
follow-up a further two months. The bulk of the work was planned to
take place one full day per week but it soon became clear that more time
would be needed. Individuals in the community, some with mild
disease, had to be allowed flexibility in arranging appointment times,
which necessitated spending three or four evenings per week and several
hours at weekends visiting patients. For every individual with AD
identified, many families with no affected members had to be seen.
Generally, women with young children were at home during the day and
could be contacted easily, but adults with full-time jobs had to be
accommodated outside normal working hours. Most patients cooperated,
but some seemed reluctant to participate: one 20 year old man failed to
attend four appointments and was never seen for follow-up.
The sampling scheme described in Chapter 2 produced three sampling
groups: families with a member recorded on computer as having eczema
(the computer group), families with a member aged below 2 (the under 2
group), and families included in the random cluster sample (the random
group). Those in the fourth stage of the sampling procedure, which
consisted of individuals who had denied the presence of an itchy rash,
yielded no further cases and this group was therefore incorporated into
the random group.
None of those approached refused to answer the questions pertaining to
the diagnostic criteria, nor did any refuse to be examined. Nevertheless,
over the subsequent 2 months, nine patients could not be recalled or
preferred to drop out of the survey.
As mentioned previously, the population is primarily indiginous, and
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therefore a language barrier was not anticipated. However a Japanese
family who spoke very little English had two members with AD and
would have proved a linguistic challenge for any investigator (Figure 3.1)
3.2 Results
The breakdown of the age distribution within the three groups described
above is shown in Figure 3.2 and the composition of all families sampled
is given in appendices 11-16. The contact rate was 93% for the computer
group, 89% for the under 2 group, and 87% for the random group, and in
total 2,365 subjects were sampled, 24% of the practice population.
The one year period prevalences of AD for the different age groups are
shown in Table 3.1 and demonstrate a steady decline with increasing age.
The overall prevalence age-standardised to the Scottish population for all
age groups was 2.3%. Only 52% of patients with AD were aged between 2
and 15, leaving almost half of AD patients in the poorly studied groups
below the age of 2 and over the age of 16. Thirty-eight per cent of all
patients with AD were over 16. The one year period prevalence in this
group was 1.2% dropping to 0.2% in the over 40's. The mathematical
calculations involved in arriving at these results are detailed in
Appendix 10 and the raw data are contained in Appendices 11-16.
The prevalences of active eczema are also displayed. While 66% of
individuals below the age of 16 were in remission at the time of
examination, only 47% of adults over 16 were in remission. Sixty-five
per cent of patients diagnosed as having AD had active eczema at the
time the diagnosis was made. The male predominance with a ratio to
females of 1.5:1 among infants under 2, was reversed in older age groups.
3.3 Discussion
3.3.1 Methods
Community studies are ideal target populations in several respects. They
represent a complete cross-section of society and are therefore unbiased if
sampled correctly. However, they are laborious, time-consuming and at
times demoralising. The intrinsic problems of contacting subjects is a
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source of many frustrations.
The present study has some clear benefits. All patients were seen by, and
the data collected and analysed by one investigator, a dermatologist in
training. This eliminates the possibility of bias from non-specialist
workers or variation in methods of data recording.
Further attributes of the design are that social class, age distribution and
seasonal variation were all accounted for, and any bias arising from these
sources should be minimal.
Two minor criticisms are that the population may not be entirely
representative of the U.K. because the Livingston community is
predominantly white, and it is semi-rural and cannot be compared
directly to a city population.
The contact rates achieved in this study are very high for a population
survey. Any bias in our estimates will be small and the results will stand
comparison with any other population survey. As reported above, using
our sampling scheme we identified 155 patients with AD from an
estimated 225 in the whole practice, despite only seeing 24% of the
practice population. Had we used a simple random sample of 24% we
would have expected to identify only 56 patients with AD. This would
have reduced the number available for the costing and quality of life parts
of the study by two thirds, and detracted from the accuracy of these
results.
The U.K. Working Party's diagnostic criteria proved ideal for use in a
community setting. There were not thought to be any cases of AD that
were missed by the criteria. Two adult patients who fulfilled the
diagnostic criteria did not have AD; one had nickel dermatitis causing
active eczema on her neck while the other was a man with pityriasis
versicolor. Both these patients were excluded.
3.3.2 Infants
The one year period prevalence for infants under 2 was 9.8%. The
epidemiology of AD in infants has been neglected possibly because, until
now, there has been no reliable means of separating those with AD from
other skin problems such as seborrheoic eczema. Reports from New
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Zealand of a lifetime incidence of 20.4% in the under 3's seem
unrealistically high and suggest that the inclusion criteria used were not
robust (Fergusson et al, 1981). Falk, using medical records in a
retrospective study, did not separate infants and estimated the lifetime
incidence of children aged 0-4 as 15% but the diagnosis was made
retrospectively from medical records (Falk, 1993). These figures may be
comparable with ours because the lifetime incidence will be higher than
the 1 year period prevalence, but without a detailed knowledge of the
natural history of AD a direct comparison is invalid.
3.3.3 Children
Measurement of AD frequency in children has been the aim of many
research projects. Schoolchildren provide an accessible, well-defined and
stable population that contains a large proportion of sufferers, and
consequently, many researchers have focused on this age-group to the
exclusion of others. Among the many recent studies , the most reliable
are the twin studies from Denmark and a recent study from Sheffield,
which cover the 2-11 year age groups (Schultz larsen et al, 1986; Schultz
Larsen, 1993; Kay et al, 1994). Given the lower prevalence in Scotland
compared with the rest of the U.K., and the differing methodology, these
studies yield similar prevalences to ours and confirm the high prevalence
in the 2-11 year age group.
Older children have proved much less popular as a target of concern but
have a reported point prevalence of 3% in the 12-16 year age group and a
detailed study from Finland has found a prevalence of 3% in 17 year olds
(Larsson & Liden, 1980; Saarinen & Kajosaari, 1995). It appears from these
data and our own that the prevalence of AD declines after the age of 12.
The sex ratios found in this study are at variance with previous reports
(Table 1.6). They indicate that AD is more common in male infants in
whom there is a M:F ratio of 1:0.6, while in the over 2s the ratio is
reversed with an overall figure of 1:1.4. However, other published
reports have been based on children rather than infants, and as such, our
results for the over 2s correspond to previous reports.
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3.3.4 Adults
Information on the prevalence of AD in adults is almost non-existent.
The Lambeth study, now almost 20 years old, gave a prevalence of 12.5%
for ages 35 to 54, suggesting that many conditions other than AD must
have been included under the banner of 'eczema' (Rea et al, 1976).
Norwegian Lapps have been studied throughout their age range (Falk,
1993). The results, however are inconsistent, possibly as a result of the
methodology. The author used medical records to assess 'eczema ever', a
method that may be suitable for examining children, but the lifetime
medical records of adults are unlikely to be complete or accurate. For
example, a lifetime incidence of 0.4% in the 50-59 year age group suggests
that AD among children 50 years ago was very uncommon. This would
be a dangerous assumption to make and casts doubt on the prevalence
figures. The only other adult figures published in the USA used national
health statistics and cannot be considered reliable data (Johnson &
Roberts, 1978).
We have shown in this cross-sectional, community study that AD is most
common in infants and becomes progressively less common in the older
age groups until over the age of 40 when it becomes relatively
uncommon. Other studies suggest a rising prevalence in children and if
this shows a cohort effect it will be reflected in the adult population,
resulting in a commensurate increase in the proportion of adults affected
(Williams, 1992). Young adults with severe, disabling disease form an
expanding proportion of the community. It is clear from the prevalence
figures of active eczema in table 3.1 that an adult with AD is more likely
to have active disease than a child which lends weight to the argument
for further research focused on the many young adults with AD.
We are therefore left with no studies on AD in adults with sound
methodology that can be compared with ours. The finding of 37% of AD
sufferers are over the age of 16 and that the proportion of adults with
active disease is higher than among children serves to emphasise the
burden of disease in adults.
50
Table 3.1.
One year period prevalences with standard errors, point prevalence of
visible eczema and sex ratio.





<2 9.8% (0.5) 7.5% 1:0.6
2-11 8.1% (1.5) 2.5% 1:1.5
12-15 2.2% (0.8) 1.1%
16-24 2.1% (0.5) 1.3% 1:1.7
25-40 2.0% (0.7) 0.9%
ova-40 0.2% (0.15) 0.1% 1:1.3
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Figure 3.1





Numbers by age in each sampling group with those who could not be
contacted in brackets. Group A represent the whole practice population.
Group B is the group seen and sampled from those families containing a
member with GP diagnosed eczema, and group C comprises the families
of the under 2s who were examined. Group D includes those who were
not sampled in groups B and C. Group E is a random cluster sample of























































One hundred and fifty five of those examined in the community fulfilled
the diagnostic criteria for AD and were studied in detail: 103 from
sampling stage 1, 38 from stage 2, 14 from stage 3. Sampling stage 4
produced no further cases. Of these the costing assessment was completed
by 146 patients or parents: 19 subjects were aged less than 2, 58 aged 2-16
and 69 aged 16 and over.
Personal costs and Health Service costs are shown in Table 4.1, and the
raw data are shown in Appendix 17. The skewed distribution of the costs
illustrated in Figure 4.1 makes it difficult to quote summary statistics.
Means are useful for extrapolations while medians are representative
averages. The mean or median is quoted where appropriate. 58 lost
working days and 17 lost school days were attributable to AD in this
population of 146 patients over a 2 month period.
4.1.1 Personal costs
Over a 2 month period, the mean personal expenditure was £25.90 and
the maximum spent was £546, the majority due to salary loss. Three
patients spent over £300 and ten spent over £100. Some patients in
remission had no expenditure attributable to AD, and this included 45%
of those aged less than 16, compared with 26% of those over 16, a
difference that was statistically significant (X =7.47, P<0.01). Expenditure
in the under 2 group was significantly lower than that in the older age
groups with a ceiling of £40. There was a difference between the 2-15 age
group and over 16 age group (medians £0.50 and £6.73).
Prescriptions accounted for 7% of patient costs. Patients below the age of
16 are not required to pay prescription charges, and of the 69 aged over 16
years, only 28 paid for a prescription.
54
Treatments bought OTC comprised 21% of the total. These consisted
mainly of emollients, bath additives, shampoo and evening primrose oil,
and the percentage spent on these items by age is shown in Figure 4.2.
Very little was spent by adults on bath additives and more was spent on
shampoo compared with younger groups. There was no sex difference.
There was a substantial salary loss but the largest part of expenditure by
patients was on clothing and laundry. Other expenses consisted of visits
to the Royal Homeopathic Hospital, Glasgow by 2 children, herbalist
advice to one adult and a visit to London for Chinese herbal treatment by
one child and his mother.
4.1.2 Health Service Costs
The mean 2 month cost to the Health Service was £16.20 and the
maximum attributable to one patient was £177.07. Ten patients cost the
Health Service over £50 but only 2 cost over £100. The median cost in the
2-15 age group was significantly higher than that in the over 16 age group
(£10.86 and £6.22) while that in the under 2 group had a median of £0.00,
but this was not significantly different.
Treatments accounted for the largest part of health service costs: 38% were
on emollients or bath additives, 32% were on topical steroids, 10% on
bandages and the remaining 20% on antihistamines, shampoo, antibiotics
and evening primrose oil.
Topical corticosteroids can be separated into four potency categories: very
potent, potent, moderately potent and mildly potent. 89% of prescribed
steroids were mildly potent or potent; 68% of that prescribed to adults
were potent while 69% prescribed to the younger age group were mildly
potent.
GP consultations accounted for almost 30% of costs, and hospital
consultations comprised only 6% of costs.
4.1.3 Hospital costs
The 2 monthly mean cost to the Health Service of the more severely
affected cohort attending the RIE was £415 (up to £1,500 for one patient),
63% of which was incurred by the hospital and 34% by the GP's. The
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maximum personal cost was £1,225 (mean £325) over 2 months, 75% of
which was due to loss of salary.
4.2 Extrapolation to the wider population
The information provided by the sampling scheme, detailed above, can be
extrapolated to the whole practice population of approximately 225 AD
patients. The estimated total annual cost of treating AD in this practice of
9,786 was £50,005; 58% was incurred by patients and 42% by the Health
Service. An estimated 427 working days and 170 school days were lost
annually.
Any projection to a wider population is subject to greater error, but if
these results were representative of the whole country they would add up
to a total annual expenditure in the U.K. of £297m, 58% of which would
be borne personally by patients. The estimated annual cost to the Health
Service would be £125m. If the cost to society of lost working days is
included, the total cost in the U.K. is £465m, a per capita cost of £7.38 per
annum.
4.3 Discussion
Several aspects of economic assessment are of central importance to
clinicians. Knowledge of therapeutic cost-effectiveness must become an
essential part of the national allocation of scarce resources, and may be
used to identify areas where savings can be made (Detsky & Naglie, 1990;
Evans, 1990; Robinson, 1993). Furthermore this knowledge should
demonstrate the value of certain treatments which might appear to be
expensive and inefficient. Any assessment of costs should include those
borne by the Health Service, by the sufferers and their families, and any
other costs borne by the rest of society (Robinson, 1993). This appears to be
particularly important for patients with AD, and perhaps other
dermatological disorders, as an estimated £297m per annum is borne by
patients themselves.
Extrapolation of these data to the wider population of the U.K. should be
interpreted cautiously, but the final estimate of the cost is likely to be an
underestimate for the following reasons:-.
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1. The prevalence of AD in Scotland is less than in the rest of the U.K.
according to the 1970 National Child Development Study (Golding &
Peters, 1987).
2. The general practitioners in the study practice are low prescribers
(Scottish Prescribing Analysis, 1994).
3. None of the patients in the study population had required hospital
treatment during the course of the study.
4. All patients lived within walking distance of the health centre, and
this minimised travel costs.
5. The cost to society of time spent by carers looking after dependants is
not included.
The data do, however, give some indication of the magnitude of the
problem with an estimated national cost of £465m.
Chronic skin diseases differ from most other medical conditions when
their costs are being assessed. A plethora of OTC preparations is available
for problems ranging from acne to warts. Remedies for treating dry skin
conditions like AD are particularly numerous, and vary greatly in their
price. Articles in the media often advertise new expensive 'holistic'
treatments that claim to cure eczema or psoriasis, but at a price. A further
drain on patients' resources comes from the need for new clothing or
bedding, and from the laundry costs which accounted for 45% of expense
to patients in the whole study, and 63% of the costs to families with
children aged less than 16. One ten year old boy, for example, needed new
cotton sheets every 2 months, partly because of repeated washing, but also
because nocturnal scratching led to extra wear and tear on the sheets.
Only a few attempts have been made to quantify the cost to the health
service of medical treatments in the UK and direct comparisons are
impossible due to differences in methodology and in spectrum of disease.
The cost of treating venous ulceration has been estimated to be £400m, or
£6.73 per head of population, a figure close to that for AD (Bosanquet,
1993). The total annual per capita cost of treating benign prostatic
hypertrophy has been estimated at £1.04-£1.53 (Drummond et al, 1993).
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The per capita cost of treating strokes, which usually require prolonged
in-patient therapy, was recently estimated to be £18.78 annually in
Scotland (Isard & Forbes, 1992). Accurate evaluation of the economic
impact of AIDS has proved to be impossible (Postma et al, 1993). Few
would have expected the economic burden of these systemic conditions
so closely to resemble that of AD.
The financial impact of severe AD has considerable repercussions on
sufferers. Adults with AD have to pay for prescriptions and are further
saddled by loss of salary and high clothing and laundry expenses. We
have shown that an individual attending hospital can spend as much as
£1,225 (mean £325) over a 2 month period; the financial burden is clearly
heavy.
The continuing rise in the cost of providing health care calls for a more
rigorous examination of clinical effectiveness. When treatment
outcomes are shown to be similar, cost effectiveness becomes a central
variable in drawing conclusions about clinical practice. Costing is
important to help clinicians make rational decisions about resource
allocation, and it is therefore important that clinicians have an




Mean annual costs of treating AD.
Cost to patient (%age)
Under 2 2-11 Over 16 Total
1. Treatments-prescriptions £11.00 £11 (7.2%)
-OTC preparations £1.60 £9.90 £19.50 £31 (21.0%)
2. GP consultations £0.06 £0.04 £0.15 £0.25 (0.2%)
3. Hospital consultations £0.24 £11.28 £0.48 £12 (8.0%)
5. Salary loss £0.92 £22.08 £23 (15.0%)
6. Clothing/laundry £3.50 £45.50 £21.00 £70 (45.0%)
7. Other expenses £1.20 £4.80 £6 (4.0%)
Total £5.40 £68.84 £79.01 £153
Under 2
Cost to patient (%age)
2-11 Over 16 Total
1. Treatments-prescriptions £10.71 £27.72 £24.57 £63 (65%)
2. GP consultations £7.84 £8.40 £11.76 £28 (29%)
3. Hospital consultations £0.30 £5.70 £6 (6%)
Total £18.55 £36.42 £42.03 £97
Table 42.
Annual per capita cost of treating AD
compared with other medical conditions
UK Atopic eczema (this study) £7.83
Venous ulceration £6.73
Stroke in Scotland £18.78
Benign prostatic hypertrophy £1.04-£1.53
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Figure 4.1
Expenditure by Patients and NHS in 2 months
No. of patients
AO-£10 A10-A20 A20-A30 A30-A40 A40-A50 A50-A60 over £60







Percentage spent by patients broken down by
age, on topical OTC treatments
Percentage
spent







Quality of Life in Atopic Dermatitis
5.1 Methods in practice
Both the DLQI and PGI were interviewer administered. It generally took
no longer than 5 minutes to complete both questionnaires.
After several individuals had completed the PGI, a list of core areas or
activities most commonly cited could be used as a prompt for subsequent
patients. There is a stark contrast between the approaches of the DLQI and
the PGI to the measurement of quality of life. The essential difference is
that the DLQI is a rigid questionnaire consisting of 10 fixed items while
the PGI is generated by the respondents who select the items they believe
are most important and these will vary between patients with the same
skin disease according to their circumstances.
5.2 Results
Of the 155 patients identified with AD, 146 completed the quality of life
part of the survey. This included 56 adults on whom most data were
collected. The raw data are shown in Appendices 18 and 19.
5.2.1 Dermatology Life Quality Index
The DLQI scores varied from 0-27 out of a possible maximum of 30, but
only 2 patients scored over 15, the mid-point in the scale (Figure 5.1). This
distribution reflects the range of severity of AD in the community, most
patients having a low score and only a few with severe AD having high
scores. The mean scores for individual questions are shown in Table 5.1.
Question 1, which asked about symptoms of itch, pain and stinging,
yielded the highest score of any individual question, followed by
Questions 2 and 4, which deal with embarrassment and clothing.
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The results of the one-year DLQI were compared with those of the
standard DLQI using a paired Wlicoxon Test. The one-year questionnaire
yielded significantly higher scores than the standard DLQI (PcO.OOl).
5.2.2 Patient Generated Index
The total scores were distributed inversely to the DLQI, over the whole
range of 0-100. The eighteen areas or activities, cited by patients in the PGI
as being influenced by their AD, are shown in Table 5.2. The first 10 items
listed, correspond to the ten questions of the DLQI but several other
activities, particularly sleep and swimming, were cited often and are
clearly relevant to AD patients.
5.2.3 Children
The questionnaire used for children is shown in Appendix 9. There were
47 children aged 5-15. Two were withdrawn by their parents with no
reason being given, and a further six could not be interviewed with their
parents during the study period. Some were too young to understand the
questions. That left 39 children, three of whom were unable to complete
Section A. Sections B and C were all completed by parents of all 39
patients, Section B referring to the child's disease and Section C referring
to the effect on the family.
The median score in Section A was 3 while that in Section B was 5 and
that difference was significant using the paired Wicoxon summed rank
test. The median for Section C was 2 with a possible total of 39.
Eleven parents responded to the PGI about the way their lives were
affected by their children's AD. The most frequently cited effect was sleep,
followed by necessity for nagging about applying topical treatments and
the inconvenience of regular treatment. The median score was 60 with a
range of 0-95.
5.2.4 Validation of the DLQI with the PGI
The correlation between results from the DLQI and PGI was -0.52
(PcO.OOl). The value is negative because low scores in the PGI and high
scores in the DLQI represent poor quality of life and this significant value
means there is a strong relationship between the two. However the value
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is not so high as to suggest that the PGI and DLQI have identical
properties.
A definite pattern emerged on the scattergram displayed on Figure 5.2.
The PGI scores (median 38.5) are spread more evenly over the complete
range than the DLQI scores (median 5.5); in the latter, only two
individuals yielded scores of over 15, the mid-point of the scale.
Nevertheless one might expect those with low scores in the DLQI to have
high scores in the PGI. In fact many scored low on both measures, and
this suggests that the apparently poor life quality registered by the PGI is
not reflected consistently by the DLQI.
Correlations between scores in the PGI and scores in individual questions
of the DLQI are shown in Table 5.1, and indicate that the PGI correlates
with Questions 1-5 of the DLQI, with significance levels shown. In
questions 2-5 of the DLQI the PGI scores of patients who scored 0 were
significantly greater than those who scored 1-3. In questions 1 and 9,
numbers precluded the test from being carried out, and in the remaining
questions there was no significant difference (Table 5.3).
In the light of these results, a 'mini-DLQI' was constructed using only
questions that showed a significant correlation with the PGI, questions 1-
5, yielding a possible total score of 0-15. Results from this 'mini-DLQI'
were also significantly correlated with the PGI (r=-0.57, P<0.001) and the
scattergram with those from the PGI is shown in Figure 5.3.
Thirty six individuals mentioned areas or activities that were not part of
the DLQI, while 20 patients identified only areas included in the DLQI.
The correlation coefficients for these groups with the PGI were -0.41 and
-0.58 respectively, both of which were significant (P<0.01).
The data evaluating the economic burden of AD patients and on the
health service are detailed in Chapter 4. The DLQI was significantly
correlated with total cost (r=-0.34, P<0.01) but the PGI was not (r=-0.23,
NS). Health service costs alone were significantly correlated with both the
DLQI (r=-0.47, PcO.OOl) and the PGI (r=-0.36, P<0.01), but the patient costs
did not correlate significantly with either.
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5.3 Discussion
The DLQI has been validated in general dermatology patients, but not
specifically in those with AD. In one sense, therefore, it is a suitable
criterion of validity against which an untried quality of life measure like
the PGI can be assessed (Streiner & Norman, 1990). Patients' PGI scores
correlated moderately well with their overall DLQI scores. In addition,
those features measured by the DLQI which one would expect to have the
greatest impact on perceived quality of life - itch, embarrassment, choice
of clothes, social life - had the highest correlations with the PGI. This
strongly supports the validity of the PGI as a quality of life measure in
dermatology.
Perhaps more important were a number of areas mentioned in responses
to the PGI which may be highly relevant to AD, such as sleep and
swimming, but which are not included in the DLQI. Conversely, the
DLQI includes questions unlikely to be of great relevance to patients with
mild to moderate AD. This is borne out by the low mean scores for four
of the DLQI questions, their poor correlation with the PGI, and the higher
correlation of the 'mini-DLQI' with the PGI.
Results from the two groups of patients (outlined in the methods section),
one quoting only areas contained within the DLQI, and the other quoting
areas outwith the DLQI, both showed significant correlation with the PGI,
although the latter group showed a lower correlation. This suggests that
some areas included in the DLQI are not necessary for assessing disability
in AD, and others not included in the DLQI are important to AD patients.
These results are echoed by the distribution of DLQI and PGI scores on
Figure 5.2: the five questions in the DLQI that correlated with the PGI can
contribute a score ranging from 0-15 which, with the exception of two
individuals, was the range of scores achieved on the DLQI (Figure 5.3). In
contrast, the PGI scores were more widely spread throughout the range of
0-100, which perhaps implies that the PGI is a more meaningful and
relevant interpretation of life quality for patients with AD in the
community in the context of patients' daily lives.
The WHO has published a model of disability based on three elements.
These are: loss or abnormality- i.e. impairment; its consequence on
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performance of an activity- i.e. disability; and the disadvantage in
fulfilment of a role- i.e. handicap. In a sense these form a spectrum
ranging from impairment to handicap, from the objective to the
subjective, and from the functional to the social (WHO, 1980; Ebrahim,
1990). Impairment can be measured purely on clinical or laboratory
criteria, but handicap must be assessed by the patient. The DLQI and PGI,
because of their nature are measuring health and quality of life at
different parts of this spectrum. The DLQI concentrates on features that
include physical symptoms and so is placed closer to 'impairment'. On
the other hand the PGI is a subjective valuation, initiated by the patient,
and is therefore closer to 'handicap'. This is reflected by the results of the
validation with cost as an objective measure of impairment: the DLQI
correlates more highly with it than the PGI. It may also be true that the
DLQI is more responsive to small, but clinically significant changes in
health or health-related quality of life, which makes it more suitable for
routine use, especially if self-administered. However a more concise,
user-friendly version of the PGI has been developed, and if fully validated
in the dermatological setting, may be a good measure of handicap (Cotton
et al, 1995).
What are the implications here for clinicians assessing the value of
treatment for patients with AD? It must be remembered first that our
patients were selected from a community population, and in general had
less severe disease than in a hospital-based sample. However, the DLQI is
not a specific measure of quality of life in these patients. Certain
questions could be discarded, or replaced with questions about sleep,
contact with animals etc., to produce a more valid, condition-specific
instrument. In contrast, the individualistic, patient-centred PGI is a
measure with considerable pertinence for patients with AD.
If the PGI is to be recommended to evaluate treatments for AD, further
research is required to assess its responsiveness to changes in perceived
health or quality of life over time. The numerous skin conditions cause
a wide variety of changes in patient's lives. As an open-ended
questionnaire, the PGI may be suitable for use over a range of
dermatological conditions, but it must also be shown to be reliable, and
adaptable.
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The conclusions one can draw from the children's quality of life results
are limited. Validity cannot be tested on one questionnaire, but it is
interesting to observe the difference between parts A and B that children
score their disease higher than their parents. The implication is that
parents' perception of the effect on their childrens' lives is greater than
the child's perception. Perhaps children grow up with AD being such an
intrinsic part of their lives that it becomes 'normal'. The parents,
however, appreciate the abnormality of their child's skin.
The effect of a child's disease on the family has always been recognised.
The PGI singled out sleep loss and the psychological stress of constant
reminding about topical treatments as being the worst aspects of having a




The correlation between the PGI and individual questions of the DLQI.
Question No. in DLQI Mean score Correlation with PGI
1 1.7 -0.36 *
2 1.1 -031 "
3 0.5 -0.39 *
4 0.86 -0.42 *•










Areas or activities cited in the PGI as being influenced by the patients' AD.
Area or activity No. of citations (%)
DLQI1 0
DLQI2 - Embarrassment 15 (27%)
DLQI3 - Home and garden 25 (45%)
DLQI4 - Clothes 7 (13%)
DLQI5 - Social & leisure 4 (7%)
DLQI6 - Sport 7 (13%)
DLQI7 - Work 19 (34%)
DLQI8 - Relationships 2 (4%)
DLQI9 - Sexual 0





Warm weather 3 (5%)









Comparison of PGI scores, using a t-test, between those who scored 0
and those who scored 1-3 in individual questions of the DLQI.




DLQI2 0 20 69 P<0.001
1-3 36 36
DLQI3 0 37 57 P<0.005
1-3 19 30
DLQI4 0 31 57 P<0.05
1-3 25 36
DLQI5 0 38 57 P<0.001
1-3 18 28
DLQI6 0 45 51 NS
1-3 11 32
DLQI7 0 31 51 NS
1-3 25 43




DLQI10 0 38 53 NS
1-3 18 36
NS = not significant
Figure 5.1
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Conclusions and the Future
6.1 The Prevalence of Atopic Dermatitis
6.1.1 The place of epidemiology in atopic dermatitis research
AD research is advancing on many fronts. These range from genetics and
molecular biology at one end of the spectrum to epidemiology at the
other. Genetic studies indicate that atopic diseases run true to type within
families: those whose relatives have AD, for instance, are more likely to
have AD (Diepgen & Fartasch, 1992; Dold et al, 1992). Atopic diseases are
also more likely to be inherited from maternal atopy than paternal atopy
whichever atopic disease is implicated (Ruiz et al, 1992; Savin, 1993).
Genetic linkage of atopic IgE responses to chromosome llql3 was first
proposed in 1989 and has since been confirmed by other workers
(Cookson et al, 1989; Young et al, 1992; Collee et al, 1993; Shirakawa et al,
1994a). Examination of polymorphisms of the chain gene of the high
affinity receptor for IgE are associated with atopy and, when inherited
maternally, identifies a risk factor for atopy (Sandford et al, 1993;
Shirakawa et al, 1994b; Hill et al, 1995)
Immunocytochemistry has given us the tool to separate two T helper cell
subsets, TH1 and TH2, on the basis of their cytokine production (Zachary
et al, 1985; Mosmann & Coffman, 1989; Sowden et al, 1992). Active disease
in patients with severe AD is associated with activation of lymphocytes
that are predominantly TH2. There is now evidence that abnormalities in
monocytes and Langerhans cells alter the function of T cells to influence
the immunological defects associated with AD (Hanifin & Chan, 1995).
In parallel with this revolution in the genetics and immunology of AD,
progress in epidemiology has continued (Schmied & Saurat, 1991). New
methods like immunocytochemistry have their counterparts in
epidemiology. Researchers have struggled with serum IgE and other
invasive diagnostic tests (Hanifin & Rajka, 1980). However the whole
concept of AD being an allergic disease has been thrown into disarray by a
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literature review that analysed thoroughly the evidence for and against a
role for IgE mediated hypersensitivity reactions in AD (Halbert et al, 1995).
The conclusion was that allergy may be an aggravating factor in some
patients, but is not central to the pathogenesis of AD. It should occasion
little surprise that serum IgE has proved to be unnecessary for diagnosing
AD and has been found to be significant in only 20% of patients with AD
(Svensson & Mansson, 1985). The U.K. Working Party's diagnostic
criteria are non-invasive and have paved the way for community studies
that can now have consistent methods of diagnosis and this will reduce
sources of error in estimates of prevalence. They have opened the way for
uniformity in community studies.
New discoveries are helping to elucidate the aetiology. Research has
shown a difference in the prevalence of AD between East and West Berlin
which narrowed after the Wall was destroyed (Diepgen, 1995).
Prevalences differ between urban and rural communities (Lynch et al,
1984) and between different ethnic groups in the same environment
(Williams, 1995b). The further epidemiological work required to pinpoint
the reasons for these differences promises to provide major advances in
our understanding of AD.
6.1.2 Prevalence data in perspective
The community studies of AD were listed in chronological order in
Chapter 1. The number of prevalence studies in the last decade has grown
but there has been no attempt to introduce uniformity of design. The
impression is of haphazard planning with very little consideration of the
best methods to use. It is only by applying consistent methodology,
similar age groups, diagnostic tools and measures of frequency that
populations can be compared with a reasonable degree of certainty. There
seems little point in publishing successive reports of prevalence of AD
without improving and standardising methods.
For purposes of comparison with the LADS the best recent prevalence
studies in the U.K. have been those from Birmingham and Aberdeen
(Kay et al, 1994; Ninan & Russell, 1992).
The first of these examined a general practice of 13,314 on the outskirts of
Birmingham. The parents of all children aged 3-11 were sent a letter
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asking if they would like to participate in a health survey. This produced
an excellent response rate of 97.6%. An interview was conducted by one
of the GPs, referring to the case notes to determine the one-year period
prevalence and lifetime incidence. Social class, ear-piercing and
associated asthma were also recorded.
AD was defined as "an itchy, often relapsing and lichenified dermatitis
that tends to affect the face and limbs in infants and also the popliteal
fossae in children 18 months and over". This is the first major
shortcoming of this report. Every aspect of this definition is vague, and
with words like 'often' and 'tends to', the possibility of misclassification is
enormous. There is no clear demarcation to discriminate 'cases' from
'non-cases' of AD.
Kay and colleagues quoted one-year period prevalences and lifetime
indicences. The former are less liable to variation due to memory
distortion. Not only might a parent have forgotten mild AD during a
child's infancy but other diseases might have been interpreted as AD.
Memory plays a small part in the estimation of the one-year period
prevalence which is consequently more reliable. However, they state the
following: "Although we have presented the age structure of our
population, in most other studies it is not known, and hence a true
comparison on the basis of age adjusted prevalence rates is not possible".
The age structure of a population is unnecessary for comparison if age-
specific rates are known, as long as the age structure of the population
under study is known. To rephrase this, if the prevalence of a disease at
every age is known, it is possible to calculate the prevalence of a new
population of known age structure. This is the attraction of an age-
specific one-year period prevalence.
In the Aberdeen study 3,942 children aged 8-13 were targeted (Ninan &
Russell, 1992). Questionnaires were sent to parents and replies were
received from 85.3%. However the questions used and the details of
diagnostic methods were not published.
The measure of frequency quoted is not discussed but is likely to be point
prevalence, and is reported to be 12.0% with M:F ratio of 1.6:1.
Unfortunately not enough information is given to allow a detailed
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assessment. It can only be assumed that if the information was not
recorded then it was not carefully considered.
Work from Scandinavia which traditionally has contributed much to the
literature on AD and where the prevalence is reportedly high, is worth
considering. Falk attempted to calculate prevalence figures for atopic
disease at all ages (Falk, 1993) but the ten line methods section contains
very little detail rendering analysis of the methodology impossible.
A twin study from Denmark concentrated on the 0-7 group (Schultz
Larsen, 1993). Even this respected study used empirical criteria that had
not been tested or validated. It also depended on a mailed questionnaire,
and parents' positive responses from a brief description of AD in an
accompanying letter before subjects were finally seen by a dermatologist.
Twins were categorised according to year of birth. There was no
significant increase found in the groups born during the years 1970-1974
and 1975-1979 and the cumulative incidence aged 0-7 was 11.5%. The
comparison of the prevalences of these groups is valid because similar
methods were used, but as a guide to the prevalence in the community,
the results are less valuable.
The design of the LADS has clear advantages over these studies in terms
of the definition of AD and confirmation of diagnosis. In the LADS one
investigator, a dermatologist, saw all subjects and followed a strict
protocol. The methods allow for seasonal variation (not mentioned in
any of the above reports) and were designed to estimate the prevalence at
all ages. This community study has advanced knowledge of the
prevalence of AD and should help to promote a standard approach for
future researchers.
6.1.3 Suggestions for the future
Prevalence studies should conform to certain basic requirements:
1. Methodological details should be described in full.
2. At present there is only one set of diagnostic criteria that has been
validated and is suitable for use in a community setting, the U.K.
Working Party's Diagnostic Criteria for AD. Until an equivalent or
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better set of criteria is available these should be used in future
population surveys.
3. The age-specific one-year period prevalence estimates are free from
the problems of memory distortion, smooth out seasonal variation
and, no matter what age is studied, allow computation of age-
adjusted prevalences.
Two areas should be developed. As patients age, the classical flexural
pattern might change and the features necessary to confirm a diagnosis of
AD may differ from those in childhood. There is also a group of patients
who, with no previous history of AD, first present in later life with a
generalised pattern that is often labelled as AD. A clinical and
immunological study of adults is necessary to clarify this.
6.2 The economics of atopic dermatitis
6.2.1 Costing in today's health service
Priorities in today's health service are changing. Rising costs have
prompted decision makers to identify ways of streamlining efficiency and
to put them into practice directly. In 1995-96 purchasers have been asked
to increase investment in at least two interventions that are known to be
effective and to reduce investment in at least two interventions that
evidence suggests are ineffective (Hayward, 1994; NHS Executive, 1994).
Directives like these create a climate of urgency to reduce costs and to
choose areas of intervention where savings can be made. It does not
eliminate choice but expensive treatments can only be justified if they are
shown to be more cost-effective than existing therapies, thus introducing
the concept of efficiency (Freemantle et al, 1995).
From these pressures there arise a demand for data to show that
clinicians' interventions are evidence-based (Smith, 1994). There is a
wealth of research in all areas of medicine but it is a cause of concern that
the information it contains has failed to influence clinical practice (Haines
& Jones, 1994). The root cause of this failure of translation to clinical
practice may be a failure of training at medical school in scientific
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methods and critical appraisal of medical research but it has led to a
recognition of the need for systematic review of existing data.
One project established in 1992 to address this problem is the Cochrane
Collaboration (Godlee, 1994). Its principal objective is to amass available
evidence from randomised controlled trials to produce guidelines for the
best treatment options from published articles. Using systematic review
and meta-analysis the information generated is distributed to
practitioners for implementation in clinical practice.
Showing efficacy alone is not sufficient. Clinical interventions must also
be shown to be effective in terms of cost, outcome and acceptability to
society (Department of Health, 1994; Robinson, 1993b). Cost-effectiveness
evaluation and a knowledge of economic analyses should be within the
grasp of all clinicians. Outcome measures are also important for
evaluating effectiveness. Traditional outcome measures are often related
to lives saved or life years gained, which may be appropriate when
dealing with surgical procedures or the management of myocardial
infarction but are not suitable in the domain of dermatology. Other ways
of spotlighting skin disease must be found. Two approaches are to count
the cost-of-illness (Rice, 1994) and to assess the impact of the disease on
the patient by measuring quality of life, both of which form the core of
data collected in the LADS.
6.2.2 Evidence of cost of atopic dermatitis
It is surprising that, until now, the assessment of cost of AD has been
ignored by dermatologists in this country. AD is known to be common
and, by nature, it provokes individuals into spending large sums on OTC
preparations. Skin disease is almost unique in this respect.
Beauty is only skin deep: by implication, beauty is dependant on attractive
skin. A whole industry thrives on this concept and patients strive to
conform to the society's ideal of 'a perfect complexion', displayed on the
cover of every woman's magazine. This tempts individuals to buy
expensive cosmetics where cheaper alternatives may be equally good. In
the assessment of the economic burden of skin disease this factor must be
accounted for and the personal cost to patients must be included
(Robinson, 1993a).
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Treatments are not the only drain on resources. The nature of AD leads
to high laundry bills. Blood and secretions cause soiling of sheets and
clothes resulting in high laundry expenses. Clothing wears out more
quickly and this results in a total estimated annual expenditure by
patients of £172m. Why, therefore, has the issue of patient costs never
been addressed?
A central organisation in the debate about costs is the National Eczema
Society (NES) which is a high profile support group for AD sufferers. In
1993 the NES entered into discussion with other dermatological patient
support groups: the Acne Support Group, Dystrophic Epidermolysis
Bullosa Research Association, Melanoma network and the Vitiligo
Society. This led to the establishment of the Skin Care Campaign (SCC)
which began in February 1994, to gather data to heighten awareness of
skin disease. The stated objectives of the group are
1. To raise awareness about the importance of skin.
2. To educate the general public and opinion formers.
3. To establish the cost of skin disorders to employers, the health
service and the community.
4. To promote the need for more and improved resources for treating
skin disorders.
One of its successes has been to encourage the foundation of an All Party
Parliamentary Group (APPG) of interested members of parliament and
peers. The inaugural meeting was in April 1994 and, during its first year,
under the chairmanship of David Congdon MP, it had six meetings with
an average attendance of 50 per meeting, one of the best for an all party
group. The first meeting concentrated on school education about skin
cancer, a common and emotive skin disorder that appeals to the media.
A current inquiry of the APPG is entitled " an investigation into the
adequacy of service provision and treatments for patients with skin
diseases in the U.K.". It has planned three oral evidence sessions to
gather information that is relevant to their areas of interest.
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Cost is a central issue to both the APPG and SCC. The data generated by
the LADS should provide invaluable information for campaigns such as
these and can now be used as part of the evidence required by both groups.
The National Eczema Society has also recently highlighted another
problem that patients with severe AD encounter. Individuals with skin
disease can be so severely affected that they are unable to work or carry out
everyday household tasks yet there have been problems gaining a
Disability Living Allowance. It is only by bringing results of studies such
as this one into the public arena that skin disease will be given priority in
the health service.
6.2.3 Progress in the costing issue
The results presented in Chapter 4 are unexpectedly high and bound to
attract publicity. It is the first study that counts the personal cost to
patients as a direct result of AD. The momentum should not be lost and
further studies extending these results are necessary.
A large study in Nottingham is looking at AD in the under 5's in four
general practices. One of the aims of this survey is to assess the cost to
patients and the health service in a way similar to that in the LADS.
Although it is restricted to a narrow age band, it should provide accurate
figures that can be compared with those from our study. Another study
based at the Royal London Hospital is looking at children with AD. The
investigators have planned to use the same proforma as in the LADS but
at present it is only at the planning stage.
Our survey is primarily community based. It would be possible to obtain
more reliable figures for those attending hospital by studying a larger
number of hospital patients over a prolonged period. This could include
measures of severity and take account of repeated attendances at the Day
Treatment Centre and admissions to hospital by individual patients,
instead of simply including the most severe patients, at times of
exacerbation of their disease, as we have done. Such a study could include
all those attending hospital whether or not they are admitted for
treatment at the Day Treatment Centre or in the ward. This would
provide a different type of data, equally valuable for publicising the
burden of skin disease.
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Costs may be used as a measure of impairment during treatment and can
be calculated in a standard acceptable manner (Hall & Mooney, 1990). Do
costs reduce when patients skin condition improves? Further work on
the relationship between severity, cost and quality of life would also be
illuminating.
6.3 Quality of life
As implied previously the issues of cost and quality of life are closely
related. They can both be used as a barometer of the impact of AD. The
SCC aims to bring skin diseases closer to the public consciousness and
includes a strong emphasis on both these areas. To strengthen the case it
is vital to have a database of reliable statistics.
63.1 Implications of results
The results generated by the LADS have quantified the disability
experienced by AD patients in the community. Both the DLQI and the
PGI indicated a range of disability and imply that many patients in the
community who seldom see their own doctor, have a significant degree of
quality of life impairment. Equally the effect of children with AD on
parents and the family has been shown by our assessment of life quality in
children and parents.
The most important areas affecting sufferers were work in the home,
effect on employment, swimming, embarrassment and loss of sleep.
These are vitally important to individuals' well-being and will therefore
affect the way they function at home and in society at large. In the WHO
model of disability ranging from 'impairment' to 'handicap', these factors
are all at the 'handicap' end of the spectrum: the only way of identifying
these sources of handicap is to question sufferers using sound, well-
validated questionnaires. The ideal questionnaire should be suitable for
comparison with other conditions to focus on the importance of skin
diseases to patients.
The DLQI was published as recently as 1994, but it has already been
embraced as the standard quality of life measure in dermatological
practice. At the meeting of the British Association of Dermatologists in
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1995, three poster presentations used the DLQI to assess the quality of life
in patients with Acne, Darier's disease and Bechet's disease (Mallon et al,
1995; Harris et al, 1995; Blackford et al, 1995), conditions in which it has
not been validated and which had few representatives in the original
patients on whom the DLQI was based. Yet even in AD, one of the most
common skin diseases, we have shown it to have deficiencies. There is a
danger that the measurement of quality of life in dermatology will fall
into disrepute because inappropriate questionnaires are being used. Skin
diseases are diverse and cause a spectrum of disability that may not be
captured by a ten-item questionnaire. There are two possible solutions.
One is to use a measure that contains a sufficiently large number of
questions to cover all possible areas of disability. Such a questionnaire
would be cumbersome and unsuitable for everyday clinical practice. The
alternative is to use a quality of life measure that is flexible and allows the
patients to choose the areas or activities of their lives that are
predominantly affected. The PGI would satisfy this condition.
The PGI has not previously been used to assess dermatological conditions.
When the science of quality of life measurement was first developed, it
was not distinguished from health status measures. Quality of life was
initially promoted as a measure of outcome in 1986, as an alternative to
more traditional end points like death or myocardial infarction (Croog et
al, 1986). However, this early attempt to assess quality of life included
physical, cognitive, emotional and social function and would be better
considered a measure of health status. Quality of life should be a
uniquely personal perception of the way an individual reacts to their
health status (Gill, 1995). A review of 75 quality of life articles found the
majority deficient in several ways: they did not define quality of life; they
did not identify the specific areas of life on which they intended to focus;
and did not aggregate their results into a composite score (Gill &
Feinstein, 1994). The PGI was given special mention, along with two
other articles, for "showing promise" (Ruta et al, 1994; O'Boyle et al, 1992;
Joyce, 1994). Three attributes were suggested that a quality of life measure
should possess, based on the hypothesis that quality of life comprises
many different characteristics that are the province of the individual.
First, patients should identify the areas that are important to them.
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Second, the severity should be rated. Third, patients should be invited to
rate the relative importance of these items to their quality of life.
The PGI fulfils all these requirements. It is gaining wider acceptance and
has been shown in this study to encompass the areas that are important to
patients with AD in the general population and a new user-friendly
version of the PGI now exists (Cotton et al, 1995). When measuring
handicap rather than impairment it also has an advantage over the DLQI.
There are techniques of measuring severity, for example, in AD and
psoriasis (European Task Force on Atopic Dermatitis, 1993; Fredriksson &
Pettersson, 1978) and these are one indication of impairment, but it is
measures of handicap that are necessary for raising the profile of
dermatology.
Death is often used as the yardstick in other branches of medicine, but this
is inappropriate in dermatology where many diseases cause severe
morbidity but not mortality. For assimilating the consequence of skin
disease on the population as a whole the area of quality of life assessment
needs to be expanded.
63.2 Advances since the Lothian Atopic Dermatitis Study began
Unlike the counting of cost, quality of life assessment is developing
rapidly. Inevitably since planning the LADS there have been some
advances. One article, describing a survey of 11,500 members of the
National Eczema Society, yielded a response rate of 29% (Long et al, 1993).
The results contained in this paper may be biased on two accounts: the
population may not have been representative of all patients with AD, and
the response rate was low. They did however confirm the important
effect on work, household activities and personal relationships and a
survey of parents of children with AD demonstrated that sleep loss was
the most important area.
A follow-up study one year later targeting individuals with severe AD,
generated some interesting data (Finlay, 1994). The DLQI scores were
high. There was an average of £5,000 lost income and five lost working
days per annum. Subjects were given a brief description of bronchitis and
asked whether they considered it to be worse than AD: the majority
would rather have had AD. However, the few individuals who had both
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AD and bronchitis felt that AD was worse. 50% were willing to spend 2
hours per day on treatment to make their skin normal, and 70% would
spend one hour. Half would pay £10,000 for a cure and 75% would pay
£1,000, but when these results were corrected for income, patients were
prepared to pay up to 75% of their annual income for a cure.
A similar survey of patients with severe psoriasis included larger
numbers (Finlay & Coles, 1995). When compared with diabetes, asthma
and bronchitis, 46%, 42% and 32% thought that psoriasis would be worse,
but among those who had these conditions the percentages change to
87%, 80% and 77%.
At present prevalence studies are generally restricted to children while
quality of life studies relate to adults. This may be convenient for research
workers but is illogical. The former need more community studies of the
whole cross-section of the population. Children's quality of life
assessment is difficult, but there is now a Children's Dermatology Life
Quality Index that allows an entry into the world of disability
measurement in children (Lewis-Jones & Finlay, 1995).
6.3.3 The future
Further data on the morbidity of skin disease are needed urgently. The
PGI has provided a new and exciting avenue down which to proceed in
the pursuit of the ideal quality of life index. In the light of the results of
the LADS, we have designed a study to extend the use of the PGI to other
common skin disorders. Measures of severity will be included to validate
it fully as a measure of quality of life in a hospital-based population.
Measures of disability are required to assess new treatments or compare
existing treatments from the patient's perspective. Cyclosporin treatment
has been shown to improve quality of life, and in-patient has been shown
to be superior to out-patient treatment when patients' quality of life is
measured (Salek et al, 1993; Kurwa & Finlay, 1995). Treatment
comparisons have also been incorporated into our new study. If the PGI
performs as well in a hospital population as it has done in a general
practice then it may provide the quality of life measure we need, that is
sufficiently flexible for use across the range of skin conditions, sufficiently
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user-friendly for routine clinical use, and may give us a method of
comparing skin diseases with other medical conditions.
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OBSERVER'S RESPONSE SHEET FOR CHILDREN AGED 2-12 YRS
Name: Age:
A. Questions
1. Has your child had an itchy skin condition in the last year - by 'itchy'
we mean scratching or rubbing the skin a lot?
Yes/No




3. Has this skin condition ever affected any of the following areas in the
past - fronts of elbows, behind the knees, fronts of ankles, sides or
front of the neck or around the ears or eyes?
Yes/No
4. Has you child ever suffered from asthma (bouts of wheezing with
coughing) or hay fever (bouts of sneezing with a runny nose or itchy
eyes in the summer)?
Yes/No
5. In the last year has your child suffered from dry skin?
Yes/No
B. ?ign?





OBSERVER'S RESPONSE SHEET FOR ADULTS (AGE > 12 YRS)
Name: Age:
a. Questions
1. Have you had an itchy skin condition in the last year?
Yes/No
2. How old were you when your skin problem began?
Under 2
2-5 years
5 - 10 years
Over 10
3. Has this skin condition ever affected the skin creases in the past - by
skin creases I mean fronts of elbows, behind the knees, fronts of
ankles, sides or front of neck, or around the ears or eyes?
Yes/No
4. Do you, or have you ever suffered from asthma (bouts of wheezing
with coughing) or hay fever (bouts of sneezing with runny nose or
itchy eyes in the summer)?
Yes/No
5. In the last year have you suffered from dry skin?
Yes/No
B. $ign?











The aim of this questionnaire is to measure how much your skin has affected your life
OVER THE LAST WEEK. Please cirtce one answer for each question.
1. Over the last week, how itchy, sore,





2. Over the last week, how embarrassed






3. Over the last week, how much has your
skin interfered with you going shopping




Not at all not relevant
4. Over the last week, how much has your




Not at ail not relevant
5. Over the last week, how much has your




Not at all not relevant
6. Over the last week, how much has your





Not at all not relevant
PLEASE TURN SHEET OVER.
102
Over the last week, has your skin prevented Yes
you for working or studying? No
If "no", over the last week how much has A lot
your skin been a problem at work or A little
studying? Not at all
not relevant
8. Over the last week, how much has your skin
created problems with your partner or any of




Not at all not relevant
9. Over the last week, how much has your skin




Not at all not relevant
10. Over the last week, how much of a problem Very much
has the treatment for your skin been, for A lot
example by making your home messy, or by A little
taking up time? Not at all not relevant




Dr Robert Herd of the skin department at the Royal Infirmary of Edinburgh is
carrying out a survey of skin conditions at Howden Health Centre. He would
be delighted if you were willing to participate and will be contacting you in the
next two weeks to explain what is required. He will either telephone or visit
you at home.







TO BE RECORDED BY PATIENT
Over the next two months:
1. Please keep containers tor all creams or ointments, bandages and all
tablets for your skin which you buy from the chemist or are prescribed
by your doctor.
2. Please record The dates of all consultations with a doctor or nurse
because of your skin and all expenses involved in these.
3. Please record the dates of all visits to hospital because of your skin
and expenses involved in these visits.
4. Please record the dates of all days off work or school because of your
skin condition.
5. Please record any loss of salary as a result of your skin condition.
6. Have you required any new clothing because of your skin condition?
Have there been any extra laundry expenses as a result of your skin
condition? Could you please record the cost of these over the next
two months.
7. Have there been any other expenses incurred directly or indirectly as





Thank you for agreeing to participate in this survey of
skin disease.
In order to estimate the cost of your skin condition to
yourself and to Howden Health Centre we would like you
to keep a record over the next two months of all
treatments and other expenses as listed on the attached
sheet.
We will also ask you to complete a short questionnaire
about the other ways in which your skin condition affects
you at the end of the two month period.
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Appendix 8
The Patient Generated Index
HOW ARE YOU AFFECTED
This questionnaire is in three stages. The part you have to fill in is on page three and is
marked 'stage one', 'stage two' and 'stage three'. The instructions on how to fill it in are
also divided into three stages. You might find it easiest to read through the instructions
for stage one, then go to page three and fill in stage one, and then do the same for stage
two and stage three.
When you are filling in each stage, we would like you to think about when you were at
your worst with your eczema in the last month. If you are at your worst now, then think
about how you feel now.
STAGE ONE (please refer to page three as you read this page)
At this stage, we would like you to think of the different areas of your life, or activities in
your life that have been affected by your eczema in the last month. When you think of
areas or activities, you might think of some small area or activity which may be quite
personal and special to you like 'I cant play with my kids'.
•• We would like you to write the FIVE most important areas or activities of your life that are
affected by your eczema in the boxes provided in STAGE ONE on page three. Put one
area or activity in each box.
You may be able to think of more than five areas but you can only write down the five
most important ones.
You don't have to write down five areas of your life if you don't feel that five areas of your
life have been affected. If you have less than five, you can write 'none' in the empty
boxes and move on to stage two.
If you feel that your life is not affected by your eczema AT ALL, then just send back the
questionnaire with 'none' in each box. In this case you don't need to go on to stages two
and three.
Once you have written down the most important areas or activities that have been
affected by your eczema, you can move on to stage two.
STAGE TWO (please refer to page eight as you read this page)
Looking at page three, you will see a scale going from 0-100 in multiples of 10. This scale
is supposed to show you how badly affected you are for each of the areas or activities you
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have mentioned. A score of zero would mean that then you were at your worst in the last
month, you felt that this was really the worst you would imagine for yourself. The score of
100 is meant to represent exactly how you would like to be, in that area or activity of your
life (even if it is impossible for you to reach).
For each area or activity that you have mentioned, write down a score out of 100 that you
would give to reflect how you were affected when you were at your worst in the last
month.
You will notice that we have filled in 'all other aspects of your life' as the final 'area or
activity'. This is meant to include all the other areas of your life affected by your eczema,
but which are not important enough to go in the top five boxes. It will also include areas in
your life which might be totally unaffected, like the size of your house.
You might suffer from another illness as well as your eczema, and any other areas that
are affected by this illness would be included in this box.
Please give a score out of 100 to the 'All other areas of you life' box in the same way that
you scored the other 'areas and activities'. Even if you leave other boxes empty you must
fill in this box.
STAGE THREE (please refer to page eight as you read this page)
For the final stage, we would like you to imagine that we can grant you a wish to improve
ANY area of your life, including the areas that have nothing to do with your eczema.
Imagine that you are given 60 POINTS to improve your score in any of the areas you
have mentioned. You cannot have more than 60 points in total but you can spend them
anyway you like. For example, you could give 10 points to each area or you might give 60
points to one area. The choice is yours to split the points up any way you like, but you
cannot have more than 60 points in total.
If you don't give any points to an area of your life, you must try to imagine that this area
will stay exactly as it is.
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Go through the boxes in stage three and distribute your points to those areas or activities
in which you would most.like to improve. You can keep changing your mind until you feel
that you have reached the best distribution of points. Remember that the total across all


















All other aspects of your
life not mentioned above
You must fill
in this box
100 exactly as you would like to be
90 close to how you would like to be
80 very good but not how you would like to be
70 good but not how you would like to be
60 between fair and good
50 fair
40 between poor and fair
30 poor but not the worst you could imagine
20 very poor but not the worst you could imagine
10 close to the worst you could imagine
0 the worst you could imagine
You have finished this section. It will tell us how your eczema has affected your life and
also which aspects of your life you would most like to see improved.
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Appendix 9
Children's quality of life questionnaire
QUALITY OF LIFE QUESTIONNAIRE IN CHILDREN WITH ATOPIC ECZEMA
SECTION A; Effect of eczema on child
Questionnaire for 5-16 year olds with Atopic Eczema
Section A will be completed by the Interviewer
All questions relate to the LAST FEW DAYS
How itchy,sore, painful or stinging
has your skin been?
How much has the skin problem
affected you playing or
socialising with your friends?
Very A A Not







3. How much has your skin problem
affected you doing any sports? n □ □ n
How much has the skin problem
interfered with your school work? □ nan
5. How much has the skin problem
interfered with any of your
other interests or hobbies,
apart from the ones already mentioned?
□ n □ □
6. How much has the skin problem
interfered with your sleep? n □ □ n
How much do you get teased
because of your skin trouble
or how much do people make
comments about your skin?
n □ □ n
8. How much does having the
ointment or cream treatments
put on affect you?
9. How happy have you been
over the last few days?






10. Are there any other ways in which having the skin problem affects
you?
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SECTION B: Effect of eczema on child
Questionnaire for parent or guardian of 5-16 year olds with Atopic
Eczema.
Section B will be completed by the parent or guardian.
Please could you answer each question, describing your view of how your
child has been affected by having eczema and how this has affected you.
The questions relate to the LAST FEW DAYS.
Relationship to child: Mother Father Other
(please specify)
Very A A Not
Much Lot Little At
All
How itchy, sore, painful or stinging
has the child's skin been?
How much has the skin problem
affected the child playing or






How much has the child's
skin problem affected them
doing any sports?
□ □ n n
How much has the skin problem
interfered with the child's
school work?
□ n □ □
5. How much has the skin problem
interfered with any of the child's
other interests or hobbies,
apart from the ones already mentioned?
□ □ □ n
How much has the skin problem
interfered with the child's sleep? □ □ □ □
7. How much do you think the child
gets teased or made comments
about because of their skin trouble?




How much does having the ointment
or cream treatments put on upset
the child?
How embarrassed or self conscious
has the child been because of the
skin problem?
□ □ □ □
□ □ □ n
Are there any other ways in which you feel the child's life has
been affected by having eczema?
Ill
SECTION C: Affect of child's eczema on family
Section C will be completed by the parent/guardian
1. How much has the eczema interfered
with any family social events?
Very A A Not
Much Lot Little At
Indeed All
□ □ □ □
2. How much has the eczema interfered
with plans for food preparation? □ □ □ □







f) non prescription treatment
g) other (please specify)
How much has your child having eczema
affected brothers or sisters?
5. How much has having a child with
eczema affected the mother socially?
6. How much has having the eczema
affected the mother's work or career?
7. How much has having a child with
eczema affected the father socially?
How much has having a child with eczema
affected the father's work or career?
9. How much has having eczema affected
the following relationships within
the family:
a) child to brothers and sisters
b) child to parents
c) brothers and sisters to parents
d) parent to parent
□ □ □ □
□ n □ □
□ □ □ □
□ nan
□ □ □ □
□ □ □ □
□ n □ □
□ □ □ □
□ □ □ □
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10. How big an effect has the process , . . . i . , ,
of treating the child had on the home I ' ' 1 ' 1 "I 1
(e.g. mess from ointments)?
11. How much embarrasment or guilt i . , . ,——, . .
has been felt by you, the . ' 1 ' 1 '—-J ' '
parent/guardian concerning




Calculation of the prevalence and standard error
The statistical methods are contained in standard textbooks (Cochran, 1977).The
calculations for the 2-11 year age group are as follows where the notation is
MO = Total number in population
n = number of families in sample
yi = proportion affected in family i
y = Y/MO
The estimated number with AD in the group obtained from the practice
computer is












with finite population correction.
The estimated number in the families of the under 2s is












with finite population correction.
The estimated number from the remainder of the population is obtained from
the random sample












with finite population correction.
The estimated prevalence of AD in the population is
41.5 + 16.0 + 56.2 x 100%
1397
= 8.1%






The prevalences and standard errors in the older age groups were calculated in
a similar way. Where there were no individuals with AD it was assumed that
yi = 0.5 to estimate the variance.
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Appendix 11
Ages in families with a member with AD. Each line represents a family and


























































































































































































































































Families with one member under 2 and also containing a member with AD,






5 10, 37 13,36
6 33 0,2,5, 33
7 0,2,31 35
8 128 28









18 14 7, 26














Families from the random sample containing a member with AD, listed as in
Appendix 11.
Family Male Female
1 32 2,5, 6, 8,34
2 9,36 10,33
3 6,8,9 31
4 33 Z, 34
5 8,31 2,28




Computer families without AD
Family Male Female
1 28,56 25, 56
2 30,61 28, 61
3 32, 66 25




8 24, 27, 52 21,48
9 23,45 44
10 44 14,17,43
11 54 21, 50
12 14,18, 44 44
13 22, 48 46
14 10, 48 17,45
15 18, 22, 50 45
16 17,49 46
..-17 10,16, 41 41
18 18, 24, 51 47


































































































































22, 53 15, 47
42
17, 20, 44 45
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181 48 18, 21, 41





187 23 20, 41
188 52 52
189 24, 62 57





L 195 4,49 15,16,38
196 32 32

































13, 37 18, 37
8,42 8,13, 39
10, 41 10, 34
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221 20, 23, 44 6,44
222 12,19, 44 43
223 62 59
224 9,13 38
225 10,31 3, 7,30
226 20,45 22,45
227 62 59
228 35,59 28, 60
148
Appendix 16














13 32 1, 9,31
14 1,56 56
15 28 1,20
16 25 1, 5,6,24



















































































1, 24 7, 9, 29
1, 27 23
64 0, 20, 54
0 25, 48































0, 26 2, 25
1,3 2,6,35
3, 27 0,28
0, 2, 26 25


































































































































































The columns in the following table correspond to the items in the proforma in appendix 6
1 a Prescription costs
lb OTC costs to patients
lc Costs of treatments to NHS
2 a Costs to patients of visiting GP
2b Costs to NHS of GP visit
3 a Costs to patient of visiting hospital
3b Costs to NHS of hospital visit
5 Salary loss
6 Clothing and laundry expense
7 'Other costs'
TP Total cost to patient
THS Total cost to NHS
Age la lb lc 2a 2b 3a 3b 5 6 7 TP THS
45 3.75 0 3.12 0 0 0 0 0 0 0 3.75 3.12
10 0 6.20 30.95 0 0 0 0 0 0 0 6.20 30.95
28 0 0 13.72 0 0 0 0 0 0 0 0 13.72
7 0 0 3.68 0 0 0 0 0 0 0 0 3.68
37 3.75 0 11.31 0 0 0 0 0 0 0 3.75 11.31
17 0 0 59.91 0 0 0 7.23 0 0 0 0 67.14
1 0 0 5.49 0 0 0 0 0 0 0 0 5.49
20 21.25 0 28.88 0 0 0 0 0 0 0 21.25 28.88
9 0 0 6.39 0 0 0 0 0 0 0 0 6.39
23 8.00 0 7.46 0 9.05 0 0 0 0 0 8.00 16.51
9 0 0 21.32 0 0 0 0 0 0 0 0 21.32
45 0 0 0 0 0 0 0 0 0 0 0 0
3 0 5.04 10.86 0 0 5.00 0 0 0 0 10.04 10.86
0 0 0 3.30 0 0 5.00 0 0 0 0 5.00 3.30
34 0 0 0 0 0 0 0 0 0 0 0 0
8 0 1.10 11.21 0 0 0 0 0 0 0 1.10 11.21
2 0 9.62 0 0 0 0 0 0 0 0 9.62 0
3 0 0 13.17 0 0 0 0 0 0 0 0 13.17
29 17.00 7.30 18.70 0 18.10 0 0 0 0 0 24.30 36.80
0 0 11.40 2.47 0 18.10 0 0 0 0 0 11.40 20.57
1 0 0 8.22 0 9.05 0 0 0 0 0 0 17.27
1 0 0 4.13 0 18.10 0 0 0 0 0 0 22.23
0 0 0 16.98 0 18.78 0 0 0 16.89 0 16.89 35.76
u 5 0 2.25 8.16 0 0 0 0 0 15.40 0 17.65 8.16
13 0 0 6.11 0 9.05 0 0 0 0 0 0 15.16
8 0 0 0 0 0 0 0 0 0 0 0 0
9 0 2.00 0 0 0 0 0 0 0 0 0 2.00
9 0 0 13.68 0 0 0 0 0 0 0 0 13.68
2 0 27.60 0 0 0 0 0 0 0 0 27.60 0
7 0 0 0 0 0 0 0 0 0 0 0 0
5 0 0 2.00 0 9.05 0 0 0 0 0 0 11.05
29 12.75 10.84 32.27 0 18.10 0 0 0 17.15 0 40.74 50.37
3 0 0 18.48 0 0 0 0 0 51.96 0 51.96 18.48
33 4.25 0 1.96 0 0 0 0 0 0 0 4.25 1.96
1 0 2.19 6.61 0 9.05 0 0 0 0 0 2.19 15.66
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Age la lb lc 2a 2b 3 a 3b 5 6 7 TP THS
4 0 5.52 0 0 0 0 0 0 0 0 5.52 0
9 0 0 2.00 0 9.05 0 0 0 0 0 0 11.05
4 0 25.83 12.11 0 0 0 0 0 0 0 25.83 12.11
4 0 4.23 16.39 0 18.10 0 0 0 100.00 0 104.23 34.49
18 12.75 10.34 22.04 0 18.10 0 0 0 0 0 23.09 40.14
9 0 0 109.49 0 0 0 0 0 120.80 0 120.80 109.49
2 0 4 34-08 0 0 0 0 0 0 0 4.00 34.08
1 0 0 0 0 0 0 0 0 0 0 0 0
4 0 3.68 0 0 0 0 0 0 0 0 3.68 0
2 0 0 7.60 .50 9.05 0 0 0 0 0 .50 16.65
16 0 .98 6.22 0 0 0 0 0 0 0 .98 6.22
22 0 10.38 0 0 0 0 0 0 0 0 10.38 0
41 0 0 0 0 0 0 0 0 0 0 0 0
3 0 0 5.97 0 0 0 0 0 0 0 0 5.97
1 0 15.98 31.52 0 18.10 0 0 0 24.32 0 40.30 49.62
30 4.25 0 4.66 0 0 0 0 0 0 0 4.25 4.66
20 0 11.70 0 0 0 0 0 0 0 0 11.70 0
39 8.50 4.95 6.66 0 0 0 0 0 0 0 13.45 6.66
11 0 0 4.66 0 0 0 0 0 0 0 0 4.66
36 0 0 6.66 0 0 0 0 0 0 0 0 6.66
16 0 .50 6.66 0 0 0 0 0 0 0 .5 6.66
32 8.50 4.75 6.21 0 0 0 0 0 40.00 0 53.25 6.21
11 0 0 4.00 .50 9.05 0 0 0 0 0 .50 13.05
22 0 3.49 17.70 0 18.10 0 0 0 0 0 3.49 35.80
27 22.00 0 35.17 0 36.20 0 14.46 0 24.00 0 46.00 85.83
5 0 0 0 0 0 0 0 0 .40 0 .40 0
15 0 0 0 0 0 0 0 0 0 0 0 2.00
36 0 0 2.00 0 0 0 0 0 0 0 0 0
10 0 0 0 0 0 0 0 0 0 0 0 0
9 0 0 0 0 0 0 0 0 0 0 0 0
22 0 1.50 0 0 0 0 0 0 0 0 1.50 0
28 4.25 21.10 4.66 0 0 0 0 0 0 0 25.35 4.66
9 0 0 0 0 18.10 0 0 23 48.00 0 71.00 18.10
6 0 0 7.64 0 0 0 0 0 0 0 0 7.64
31 0 0 12.42 0 9.05 0 0 0 0 0 0 21.47
1 0 0 18.74 0 0 0 0 0 0 0 0 18.74
7 0 0 3.36 0 0 0 0 0 0 0 0 3.36
2 0 0 13.09 0 9.05 0 0 0 0 0 0 22.14
6 0 1.20 48.95 0 9.05 0 0 0 40.80 0 42.00 58.00
2 0 21.72 4.00 0 0 0 0 0 0 0 21.72 4.00
7 0 0 15.70 0 0 0 0 0 0 0 0 15.70
5 0 1.20 2.00 0 0 0 0 0 0 0 1.20 2.00
24 8.50 6.99 7.60 0 18.10 0 0 0 0 0 15.49 25.70
1 0 9.45 36.40 0 9.05 0 0 0 20.48 0 29.93 45.45
5 0 .82 8.41 0 9.05 0 0 0 4.40 0 5.22 17.46
36 4.25 26.50 2.00 0 0 0 0 0 60.00 0 90.75 2.00
11 0 24.10 33.60 0 0 270 0 0 60.00 0 354.10 33.60
3 0 0 5.60 0 0 0 0 0 0 0 0 5.60
21 12.75 0 9.60 0 0 0 0 0 0 0 12.75 9.60
13 0 0 0 0 0 0 0 0 0 0 0 0
2 0 5.60 2.00 0 0 0 0 0 50.00 0 55.60 2.00
19 0 0 0 0 0 0 0 0 0 0 0 0
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Agp la lb Ic 2 a 2b 3 a 3b 5 6 7 TP THS
10 0 8.50 6.76 0 18.10 0 0 0 0 0 8.50 24.86
32 0 22.77 2.00 0 0 0 0 0 10.00 0 32.77 2.00
10 0 0 5.28 0 9.05 0 0 0 0 0 0 14.33
40 34.00 10.34 33.62 0 27.15 13.75 116.3 440 30.00 18.00 546.09 177.07
14 0 0 0 0 0 0 0 0 0 0 0 0
7 0 0 41.41 0 18.10 0 0 0 0 0 0 59.51
2 0 52.87 18.32 0 0 0 0 0 74.80 0 127.67 18.32
47 8.50 1.75 17.95 .84 9.05 0 0 0 0 0 11.09 27.00
1 0 0 0 0 0 0 0 0 0 0 0 0
25 0 5.45 0 0 0 0 0 0 0 0 5.45 0
6 0 0 21.57 0 9.05 0 0 0 440.00 0 440.00 30.62
4 0 1.30 0 0 9.05 0 0 0 0 0 1.30 9.05
5 0 0 0 0 0 0 0 0 0 0 0 0
23 0 54.25 10.00 0 18.10 0 0 65 0 0 119.25 28.10
28 0 2.50 0 0 0 0 0 0 15.96 0 18.46 0
20 4.25 7.75 3.16 0 9.05 0 0 0 0 0 12.00 12.21
1 0 0 6.22 0 18.10 0 0 0 0 0 0 24.32
27 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 63.43 0 18.10 0 0 0 0 0 0 81.53
25 8.50 0 56.26 0 0 0 0 0 0 0 8.50 56.26
4 0 4.25 2.00 0 9.05 0 0 0 56.00 30.00 90.25 11.05
28 0 19.45 0 0 0 0 0 0 11.96 0 31.41 0
0 0 0 0 0 0 0 0 0 0 0 0 0
12 0 21.62 29.88 0 0 0 0 0 144.80 0 166.42 29.88
15 0 0 23.30 0 0 0 0 0 0 0 0 23.30
30 29.75 0 35.40 0 0 0 0 0 30.80 20.00 80.55 35.40
4 0 1.00 47.72 0 0 0 7.23 0 0 0 1.00 54.95
21 0 48.00 0 0 0 0 0 0 64.00 6.00 118.00 0
6 0 0 0 0 0 0 0 0 0 0 0 0
13 0 .20 4.66 0 0 0 0 0 0 0 .20 4.66
15 0 .20 0 0 0 0 0 0 0 0 .20 0
7 0 0 5.60 0 9.05 0 0 0 0 0 0 14.65
7 0 0 21.85 0 9.05 0 0 0 4.40 0 4.40 30.90
1 0 0 7.18 0 9.05 0 0 0 0 0 0 16.23
4 0 14.17 21.43 0 14.41 0 0 0 40.20 0 54.37 35.84
22 0 0 0 0 9.05 0 0 0 0 0 0 9.05
0 0 4.00 19.80 1.50 17.15 0 0 0 22.00 0 27.50 46.95
17 0 0 0 0 0 0 0 0 0 0 0 0
19 4.25 0 4.66 .50 9.05 0 0 0 0 0 4.75 13.71
16 0 0 6.66 0 0 0 0 0 0 8.00 8.00 6.66
23 0 0 7.20 2.20 18.10 0 0 0 0 65.00 67.20 25.30
1 0 0 17.77 0 0 0 0 0 0 0 0 17.77
17 4.25 9.00 9.14 0 9.05 0 0 0 0 0 13.25 18.19
29 4.75 3.99 5.04 0 9.05 0 0 25 0 0 33.74 14.09
34 0 0 0 0 0 0 0 0 0 0 0 0
30 0 0 0 0 0 0 0 0 73.80 0 73.80 0
14 0 133.0 0 0 0 0 0 0 0 0 133.00 0
6 0 20.50 0 0 0 0 0 0 0 0 20.50 0
54 4.75 0 6.36 0 9.05 0 0 0 0 0 4.75 15.41
32 4.75 31.84 4.66 0 0 0 0 0 0 0 36.59 4.66
20 0 1.85 4.00 0 0 0 0 0 0 0 1.85 4.00
23 0 0 0 0 0 0 0 0 0 0 0 0
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Age la lb lc 2a 2b 3a 3b 5 6 7 TP THS
4 0 0 0 0 0 0 0 0 0 0 0 0
35 0 3.00 0 0 0 0 0 0 0 0 3.00 0
10 0 3.00 0 0 0 0 0 0 0 0 3.00 0
0 0 0 15.20 0 18.10 0 0 0 0 0 0 33.30
24 4.75 0 4.26 0 0 0 0 0 0 0 4.75 4.26
20 4.75 0 4.53 0 0 0 0 0 0 0 4.75 4.53
29 0 0 0 0 0 0 0 0 0 0 0 0
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Quality of life measures in adults.
DLQI1 Standard DLQI
DLQI2 DLQI referring to previous year
Age Sex DLQI1 DLQI2 PGI
45 F 2 80
28 M 2 2 77
37 F 6 14 53
17 F 8 17 5
20 M 7 13 39
23 F 9 11 45
45 F 1 4 90
29 F 2 8 53
29 F 2 11 12
33 F 2 10 33
18 M 10 10 50
16 F 3 7 55
22 F 0 1 100
41 F 1 1 100
30 F 1 10 100
20 F 3 5 90
39 M 3 1 37
36 F 5 6 100
16 F 3 4 40
32 F 5 6 100
22 F 9 11 18
27 F 9 11 18
22 F 1 5 100
28 F 24 25 20
31 F 11 10 27
24 F 8 10 40
36 F 4 5 100
21 F 2 4 45
19 M 1 5 100
32 F 10 13 32
40 M 12 18 18
47 F 5 12 15
25 F 2 3 38
23 F 9 10 32
28 F 4 7 100
20 F 3 9 5
27 F 4 3 100
28 F 4 13 30
30 F 8 10 28
21 F 9 11 47
22 F 10 16 0














































Children's quality of life data.
Age Sex Section 1 Section 2 Section 3 Total
10 F 7 10 10 27
7 F 8 20 3 31
9 F 0 0 0 0
9 M 3 3 3 9
8 F 4 7 1 12
5 F 12 7
13 F 2 1 2 5
8 M 0 0 2 2
9 F 3 6 0 9
9 M 1 2 3 6
9 M 3 9 15 27
11 M 4 4 0 8
11 M 5 4 1 10
5 F 3 5 0 8
15 M 2 3 0 5
10 F 0 8 1 9
9 M 1 3 0 4
9 M 0 0 2 2
6 M 11 13
7 F 2 5 4 11
6 M 7 14 2 23
7 M 1 5 2 8
5 F 1 2 0 3
5 F 2 4 8 14
11 F 5 5 13 23
13 M 5 5 2 12
10 M 3 5 5 13
10 F 9 7 0 16
14 F 1 1 1 3
6 M 5 5
12 F 9 14 7 30
15 F 12 11 12 35
6 M 0 0 0 0
13 M 3 2 0 5
15 M 0 0 0 0
7 M 1 5 1 7
7 M 8 11 1 20
16 F 5 13 6 24
14 M 4 3 2 9
10 F 3 5 2 10
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ADDENDUM
The following problems with the sampling scheme outlined in chapter 2
and estimates of prevalence in chapter 3 have been identified.
1 (a) The sampling procedure selected families with probability
proportional to size. This attribute was true for families but not for
age groups within families. It follows that in the random cluster
sample in group 3 the sampling within age groups was not with
probability proportional to size. Furthermore, non-responder did not
follow any probability proportional to size rule. The estimated
numbers with atopic dermatitis within age strata cannot be assumed
to be unbiased
1 (b) The formulae used for the estimates in sampling groups 1 and 2
assume sampling with replacement. This assumption is not crucial
when the sampling fraction is low as in group 3 but is important
when the sampling fraction is high as in groups 1 and 2.
1 (c) The prevalence estimates were calculated on the basis of sampling
with probability proportional to size. In groups 1 and 2 this may
have been important.
1 (d) The estimate of variance relies on the assumption that the
proportion of family members within age strata in group 1 is
homogeneous. This is not true. However any one family member
having atopic eczema increases the probability of any other family
member of any age having atopic eczema and this reduces this
problem.
2. Bounds - ages 2-11
Cochran WG, Sampling Techniques, Third edition, p259, 9A.7. This
section the Horvitz-Thompson Estimator for sampling with unequal
probabilities without replacement. Tti is the probability of the i*h unit




where yi = number in ith unit
and Tti = the probability of ith cluster being in sample.
Then in group 1, the probability of being in the sample is related to all
ages
Tti = 0.93 (approximated as the sampling fraction)
Y = 35/0.93 = 37.6
Var (Y) = X(0.07/0.93)yi2




Y = 13/0.89 = 14.6
Var (Y) = 1.61
In group 3
id = 0.08936 for a family size 3
Tci = 0.11734 for a family size 4
Tti = 0.17077 for a family size 6
7ti = 0.19626 for a family size 7
and for two families size 4
rcij = 0.01383 etc
Y=Xyi/7ti = (2/0.17077) + (2/0.11734) + (2/0.11734)
= 79.1
Var (Y) = X((l-Jii)/rci)yi2 + 2XX((rcij -n'm))/niit) )yiyj
= 108.9 + 0.825
= 109.7
XY = 131.3
Var (XY) = 114.02
Prevalence estimate = ((37.6 + 14.4 + 79.1) / 1397) * 100%
= 7.7%
SE = (V(l14.02)/1397) * 100%
= 0.8%
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Bounds - ages 12-15
Groups 2 and 3 yielded no cases of AD. Instead of calculating the SE it is
better to quote confidence limits, with the lower limit being the frequency
of AD in group 1. The upper limit is calculated with an estimate of
variance assuming a frequency of 0.5 in groups 2 and 3.
95% confidence limits for Y are [10,13.6]
This gives 95% confidence limits for the prevalence of [1.6, 2.2]
Bounds - ages 16-24
Similar to ages 12-15
95% confidence limits for Y are [29, 34.8]
This gives 95% confidence limits for the prevalence of [1.8, 2.2]
Bounds - ages 25-40
Calculations for this group are similar to 2-11 range.
Prevalence estimate = 2.3%
SE = 0.24
Bounds - ages 41+
Similar to ages 12-15
95% confidence limits for Y are [5, 7.9]
This gives 95% confidence limits for the prevalence of [0.15, 0.24]
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Recent advances in atopic dermatitis
J.A.A. HUNTER and R.M. HERD
From the University Department of Dermatology, The Royal Infirmary, Edinburgh
Introduction
Atopic dermatitis remains, in many respects, as
strange a condition now as when Coca and Cooke
classified it in 1923.1 Its inheritance and pathogenesis
still fuel much research and controversy; its treatment
may test patients, their families and their doctors to
the limit. But real progress in understanding different
aspects of the disease has been made during the last
ten years.
Diagnosis
Sound and simple diagnostic criteria are fundamental
to all studies on the condition, especially those
which are based in the community and conducted
by those without clinical experience of atopic derma¬
titis. Williams convened a working group which has
suggested some 'gold-standard' clinical features.2 To
qualify as a case of atopic dermatitis, an individual
must have an itchy skin condition (or parental report
of scratching or rubbing in a child) plus three or
more of the following: history of involvement of the
skin creases such as folds of elbows, behind the
knees, fronts of ankles or around the neck (including
cheeks of children under 10 years); a personal history
of asthma or hay fever (or history of atopic disease
in a first-degree relative in children under 4 years);
a history of general dry skin in the last year;
visible flexural eczema (or eczema involving the
cheeks/forehead and outer limbs in children under
4 years); onset under the age of 2 years (not used if
child is under 4 years). The beauty of these criteria
is that they are simple, take under two minutes to
determine and do not require the subject to undress.
They have been carefully validated, there is good
agreement between doctors about the presence or
absence of these features, and individual doctors are
consistent in their assessment of them. Discrimination
of atopic dermatitis was impressive, with a sensitivity
of 85% and specificity of 96%. We no longer need
to depend on signs such as keratosis pilaris and fine
hair, on which dermatologists too often disagree.
The criteria do not include total IgE concentrations
in the blood, positive IgE titres to specific antigens,
positive responses to prick tests, or combinations of
these,3 although there is undoubtedly a need to
validate such tests in a similar way to the clinical
diagnostic criteria proposed by Williams' working
group.
Prevalence and epidemiology
Good population-based studies are necessary to
obtain an accurate estimate of the frequency of the
condition. Atopic dermatitis is subject to many
influences such as race and climatic conditions.4
Early reports relied on a variety of sources of data,
such as questionnaires sent to parents, health
visitor observations and government health census
statistics.5""7 Comparisons between studies is difficult
because of the different measures of frequency which
were used, such as point prevalence, period preval¬
ence or cumulative incidence, and the diversity of
populations examined. Understanding is further ham¬
pered by the retrospective approach of most studies.
One of the first published estimates of prevalence
was by Walker and Warin in 1956 using health
visitor cards.6 Their quoted prevalence of 3.1% for
infantile eczema was probably an underestimate,
because they included only cases where there was
no doubt about the diagnosis. In 1955, Eriksson-Lihr
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mentioned two large Finnish studies on the occur¬
rence of allergy in school children.8 The first, from
Turku, based on information from questionnaires to
parents, school health cards and local health centre
records revealed that 3% of 4832 children had
eczema. The second, from Helsinki involving 27 999
children aged 7-14 years, took advantage of school
health cards and medical examinations and showed
that 2% had eczema.
Since these early studies, many reports have
revealed a steady increase in the reported prevalence
of atopic dermatitis. Despite the pitfalls of making
comparisons, the evidence strongly suggests that this
increase is genuine and parallels the rising incidence
of other atopic diseases.9"14
Why has there been such an increase in the
incidence of atopic dermatitis in recent years? Several
plausible explanations are examined by Williams.9
A change in chronicity, possibly as a result of the
widespread use of topical steroids, may result in
more frequent or prolonged periods of exacerbation,
causing an apparent but false increase in prevalence.
New household cleaning materials may be acting as
disease modulators for atopic dermatitis allowing
sensitization through damaged skin. Changes of life¬
style and increasing environmental pollution are
frequently cited causes.14 Polychlorinated biphenol
levels in human breast milk have been reported as
rising in recent years, and agricultural chemicals in
cows milk provide a further source of exposure to
these chemicals in infants.15 The issue is far from
resolved, and the subject of environmental pollutants
is bound to throw up many other hypotheses to
explain the increasing prevalence of atopy.
The most recent, reliable figures are cumulative
incidence rates of 12% for 5-year-olds, and between
9% and 12% for 7-year-olds.10,11,16,17 In children
aged 12-16 the point prevalence has been estimated
at 3.0%, declining rapidly with age.18 Our unpub¬
lished data, generated from a community study of a
large general practice, yielded one-year period pre¬
valence figures of 6% for the under 2s and 13% for
the 2-12-year age group.
The epidemiology of adult atopic dermatitis has
been largely neglected. Published figures indicate a
prevalence of 'eczema' of 2-7% without atopic
dermatitis being quoted separately.7,19 The results of
our recent community study using the UK Working
Party criteria suggest a prevalence of 1% in the
over-25 age group, with a steep decline with age.
Atopic dermatitis begins in early childhood in the
majority of patients, with a M:F sex ratio of between
1:1 and 1:1.7.12 Queille-Roussel ef a/.,20 in a study
of 500 children, published figures on the age of
onset in children attending a paediatric dermatology
unit. The results are biased downwards because it
was not a cohort study, but it is of interest that 91%
of their patients developed atopic dermatitis before
the age of two, and 65% before they were 6 months
old.20 Rajka's figure of 80-90% of patients having
developed the condition before the age of seven
may be more accurate.21
Genetic aspects
Recent studies on the inheritance of atopy have been
well summarized by Savin.22 It seems clear that
atopic dermatitis, asthma and hay fever tend to run
true to type in families,23,24 although some unfortu¬
nate individuals have the full house of atopic mani¬
festations. Two studies25,26 indicate that atopy is
inherited more often from the mother than the father,
a suggestion made earlier by Cookson ef al. from
Oxford when they linked atopy, based on an IgE
definition, to markers on chromosome 11 ql 3 in
about 60% of cases.27 Linkage of atopy to 11 ql 3
has since been replicated by two other teams, a
Dutch group,28 using sibling pairs, and a Japanese
group,29 using Lod score methods. Sandford ef a/.30
have gone on to propose a theoretically attractive
candidate gene, coding for the subunit of the high
affinity receptor for IgE, which lies on chromosome
11 ql 3. All would be well if it were not for the
dissenting voices of some other groups who have
failed to detect linkage between atopy and chromo¬
some 11q.31"34 Genetic heterogeneity and method¬
ological differences may well explain the dilemma.
Immunological aspects
A fundamental defect which is specific for atopic
dermatitis, rather than common to all types of atopy,
has been difficult to establish. The many abnormalit¬
ies found in atopy, reviewed by Chapman and
Parish,35 include decreased delayed hypersensitivity
responses, decreased numbers of mature T lympho¬
cytes in the blood (particularly those with suppressor
activity), defective metabolism of essential fatty acids
which are the precursors of ecosanaid mediators of
inflammation, increased permeability of intestinal
mucosa to food allergens, abnormal signal transduc¬
tion from a and b adrenergic receptors due to
increased amounts of cAMP phosphodiesterase, and
abnormal vascular responses to histamine, nicotinic
acid and acetyl choline.
However, it is hard to believe that IgE antibody,
serum levels of which are raised in 80-85% of
patients with atopic dermatitis, does not play a
critical role in triggering the rash.36 Recent studies
have demonstrated a high-affinity IgE receptor on
human epidermal Langerhans' cells37,38 and have
shown that these cells, which are increased in
number in atopic dermatitis,39 are capable of pre¬
senting house dust mite antigen to CD4+ (helper) T
lymphocytes.40 Hauser ef al. have also found that T
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helper lymphocytes, repeatedly stimulated with hapt-
en-modified cultured Langerhans cells, produce
interleukin-4 and stimulate IgE production by B
cells.41 Although the situation in the human is not
so clear, it has been shown convincingly in mice
that there are two helper T-cell populations which
can be distinguished by the cytokines which they
produce. Th1 cells produce IL-2 and IFNy, whereas
Th2 cells produce IL-4 and IL-5.42 Interestingly, IL-4
inhibits the synthesis of IFNy and induces the syn¬
thesis of IgE in human mixed lymphocyte cultures.43
There is growing evidence that T cells from atopic
dermatitis patients are predominantly Th2 in type.44,45
It is no longer difficult to envisage that important
antigens, such as those of the house dust mite,46 are
trapped in the epidermis by specific IgE antibody
bound by the high-affinity IgE receptors on the
surface of Langerhans cells, and then processed for
antigen presentation. This encourages the local accu¬
mulation of Th2-type cells and, by the above mech¬
anisms, induces further production of IgE by B cells.
However, this sequence of events cannot explain the
pathogenesis of the rash in those atopics with no
detectable or normal levels of IgE.35 Recently, an
alternative pathway leading to the accumulation of
inflammatory cells in the skin, independent of IgE,
has been suggested. Bacterial toxins released by
Staphlococcus aureus, which colonizes over 90% of
atopic dermatitis lesions, may not only elicit produc¬
tion of IgE antibody,47 but also exacerbate atopic
dermatitis by a different mechanism. These toxins
are prototypic superantigens.48 Sensitization to such
superantigens is not necessary to prime the immune
response. Superantigens align with a variety of
class II MHC molecules outside their antigen pre¬
sentation groove and, without any cellular pro¬
cessing, may directly signal different classes of T cells
within the large family carrying a Vb type of T-cell
receptor. By these means, superantigens are capable
of inducing massive T-cell proliferation.
Assessing disability
Although atopic dermatitis is not a life-threatening
condition, it can result in considerable disability,
both physical and psychological.49 The skin is the
most visible organ in the body, and any abnormality
or blemish is immediately apparent and can lead to
stigmatization. This has been addressed principally
with regard to psoriasis and leprosy, but in recent
years there has been an increasing interest in the
impact of atopic dermatitis on quality of life.50~52
Assessment of disability is necessary for routine
management of patients, and in research for the
comparison of groups of patients receiving new
treatments53. The UK Sickness Impact Profile (UK
SIP) has been used to assess the impact of hyperten¬
sion, angina and the side-effects of new drugs, and
has been used in the validation of the Psoriasis
Disability Index (PDI).54,55 This comparison has
shown that the PDI is an appropriate and rapid
method of assessing quality of life impairment in
psoriasis. The use of an Eczema Disability Index
derived from the PDI, although initially promising,
has failed to show a clear link with the UK Sickness
Impact Profile.56,57 A new compact questionnaire
called the Dermatology Life Quality Index has
yielded promising results in the assessment of atopic
dermatitis patients.58 The reproducibility of this meas¬
ure is reassuring judging from a one-week test-retest
study, but formal comparison with the UK SIP
and PDI has yet to be completed. Our own work
suggests that loss of sleep, skin irritation when
swimming, and embarrassment about appearance
rank as the three aspects of the disease which cause
most distress to patients.
These questionnaires may be useful tools in adults
but the majority of patients with atopic dermatitis
are children. The problems of assessing quality of
life impairment in children are enormous, and this
may explain why so little work has been done in
this area and why, as yet, no measure of disability
exists for children.
Economics
The importance of atopic dermatitis lies in its high
prevalence in children, and the dramatic impact on
the lives of those who are most severely affected. It
is therefore surprising that the economics of atopic
dermatitis have been largely ignored, and that there
have been only two publications on this subject in
recent years compared with 181 dealing with the
economics of HIV infection. A conservative estimate
of the annual cost of treating atopic dermatitis in
children in the USA is $364m.59 A direct comparison
with the UK is not possible, owing to the differences
in the delivery of health care. In the UK much of
the economic burden is shouldered by the state, but
loss of employment, frequent purchase of over-the-
counter preparations, prescription charges and dam¬
aged clothing and bedding can lead to considerable
personal costs. In our own recent unpublished work,
the monthly cost to the patient can be up to £390
and the cost to the Health Service up to £650.
However, the monthly cost for the majority of
patients is very much less than this, the median
being about £3. A final analysis of this data has yet
to be completed.
Treatment
judicious local corticosteroid treatment and emolli¬
ents remain the cornerstone of treatment for atopic
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dermatitis. Useful adjunctive therapies, which have
attracted attention recently, include ultraviolet-B radi¬
ation50 and psoralen photochemotherapy (PUVA).61
Short sharp courses rather than prolonged mainten¬
ance courses are preferable. There has been much
debate about the value of gamolenic acid in evening
primrose oil. Different groups have used the same
data, obtained from placebo-controlled double-blind
trials, to support opposing views on its efficacy.62,63
Many doctors, with their therapeutic backs to the
wall, will try gamolenic acid as an adjunctive to
conventional treatment, believing that it may have a
modest beneficial effect in about a third of patients
and knowing that it has almost no side-effects. For
years clinicians have found prolonged courses of
anti-staphylococcal antibiotics helpful;64 some might
feel reassured that the discovery of bacterial superan-
tigens has given theoretical respectability to this
practice. Intermittent courses of cyclosporin A (a
drug which reduces T-cell activation), should give
hope to those atopic patients whose lives have been
made miserable with widespread and recalcitrant
dermatitis.65 The avoidance of food allergens, either
prophylactically or when food allergy is diagnosed,
remains as controversial as the place of food allergy
in the pathogenesis of atopic dermatitis. Zeiger et al.
showed that the gains when expectant mothers
practised food allergen prophylaxis were relatively
short-lived.66 If there is no doubt, on historical
grounds, that certain foods either lead to an exacerba¬
tion of the dermatitis or cause urticaria, then they
should be excluded from the diet, possibly after RAST
testing. Avoidance of contact with dust mite allergen
appears more promising.46 Genuine advances are
being made in unravelling the complexities of this
strange disease.
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Summary An epidemiological study of atopic eczema (AE), based on a semirural community in Scotland, using
sound diagnostic criteria, has yielded prevalence data for all age groups including infants and adults.
The overall 1-year period prevalence, age-standardized to the Scottish population, was 2-3%. The 1-
year period prevalence was highest in the under 2s (9-8%), and showed a continuous reduction with
increasing age. Over the age of 40, AE was found to be relatively rare, with a 1-year period
prevalence of 0-2%. Adults over 16 years made up 38% of all patients with AE.
Atopic eczema (AE) has major socio-economic
implications.1 Although the cellular mechanisms
behind the atopic phenotype have become clearer, and
powerful new treatments have been introduced,2,3 reli¬
able epidemiological data are sparse. The few studies of
prevalence have not always defined their diagnostic
criteria, and some have been based on health visitor
records or questionnaires that have relied on a parental
diagnosis. A variety ofmeasures of frequency have been
used, e.g. cumulative incidence or point prevalence. AE
in infants, and adults, largely has been ignored. The aim
of our study was to estimate, accurately, from a repre¬
sentative population, the prevalence of AE at all ages.
Methods
The study population comprised a semirural general
practice, of 9786 patients, situated in Livingston, a new
town in central Scotland. The age distribution differs
from that in the rest of Scotland, with a larger propor¬
tion of young adults, and a correspondingly smaller
proportion of adults over 65. The social class distribu¬
tion is biased slightly towards social class III, and away
from the higher and lower social classes.4
Howden Health Centre is a well-organized practice,
served by eight general practitioners (CPs). Access to
medical records was facilitated by a computerized
records system. One of us (RMH) examined all available
patients with a coding of eczema on the practice com¬
puter, together with the other members of the family, to
identify those with AE. As infants were poorly repre¬
sented in this sample, every family with a child aged less
18
I
than 2 was contacted. To estimate the number of
patients with AE in the remaining practice population
not identified on the computer, a one-stage random
cluster sample of 10% was taken, each cluster being a
family.3
The diagnosis of AE was established using the U.K.
Working Party's diagnostic criteria.6 These require a
history of an itchy skin condition, and three other
criteria, only one of which relies on examination. This
protocol was adhered to strictly. The possible effects of
seasonal variation were eliminated by recruiting
patients over a 1-year period, and by measuring the
1-year period prevalence. Prevalence and standard
errors were calculated by stratified cluster sampling
techniques, with a finite population correction.5
Results
The contact rate was 93% for patients with GP-
diagnosed eczema and their families, 89% for the
under 2s, and 87% for the random cluster sample.
Altogether, 2365 patients were sampled in these
groups, 24% of the practice population.
The U.K. Working Party's diagnostic criteria proved
ideal for use in a community setting. No cases of AE
were thought to be missed. Conversely, two adults who
fulfilled the criteria did not have AE: one had nickel
dermatitis causing eczema on her neck, the other had
pityriasis versicolor. Both were excluded.
The 1-year period prevalences of AE, for the different
age groups, are shown in Table 1, and demonstrate a
steady decline with increasing age. The male'.female
© 1996 British Association of Dermatologists
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Table 1. One-year period prevalences and standard errors (SE)
1-year period Point prevalence
Age prevalence (SE) of visible eczema
<2 9-8% (0-5) 7-5%
2-11 8-1% (1-5) 2-5%
12-15 2-2% (0-8) 1-1%
16-24 2-1% (0-5) 1-3%
25-40 2-0% (0-7) 0-9%
Over 40 0-2% (0-15) 0-1%
ratio, of 1-5:1, among infants under 2 (1-year period
prevalence for males, 11-9%, and for females, 7-2%),
was reversed in older age groups (1-year period pre¬
valences aged 2-11, 12-24 and 25+ for males, 7-7,
1-4 and 1-1% respectively, and for females, 11-4, 2-4
and 1-3%). Sixty-five per cent of patients diagnosed as
having AE had active eczema at the time the diagnosis
was made. The overall 1 year period prevalence, age-
standardized to the Scottish population for all age
groups, was 2-3%. Only 52% of patients with AE were
aged between 2 and 15, leaving almost half of AE
patients in the poorly studied groups below the age of
2 and over the age of 16. Thirty-eight per cent of all
patients with AE were over 16. The 1-year period
prevalence in the 16-40 group was 2-0% dropping to
0-2% in the over-forties.
The prevalences of active eczema are also displayed.
While 66% of individuals, aged below 16, were in
remission at the time they were examined, only 47%
of adults over 16 were in remission.
Discussion
The 1-year period prevalence for infants under 2 was
9-8%. The possible reason for the neglect of the epi¬
demiology of AE in infants is that, until now, there have
been no reliable diagnostic criteria. Recent reports have
glossed over the issue of robust inclusion criteria, which
may have contributed to a high lifetime incidence of
20-4%, in the under 3s, in one study/ The U.K. Work¬
ing Party's criteria contribute a framework for compar¬
ison between this and future studies, provided that the
format is adhered to closely.
Information on the prevalence of AE in adults is very
sparse. The figures presented in the Lambeth study,
in 1976, of a prevalence of 12-5% for ages 35-54,
suggest, as acknowledged by the authors, that many
conditions other than AE must have been included
under the banner of 'eczema'.8 There appears to be a
rising prevalence of AE in children9 and, if this shows
a cohort effect, it will be reflected in the adult population,
resulting in a commensurate increase in the proportion
of affected adults. We have shown that the decline in
AE, known to occur with increasing age during child¬
hood and due possibly to age, period or cohort effects,
continues in adult life, until over the age of 40, when AE
becomes relatively uncommon. In one sense this justi¬
fies the almost exclusive attention given to school
children but, when one considers that 38% of all AE
patients are over 16 years of age, the size of the problem
in the adult population becomes apparent. It is clear
from the prevalence figures of active eczema, in Table 1,
that an adult with AE is more likely to have active
disease than a child.
This study is unique in three respects: it uses firm
diagnostic criteria in a community setting, standard
errors are quoted for prevalences, and accurate preva¬
lence figures for adults are given. As AE is a seasonally
influenced disorder, we recommend that the 1-year
period prevalence is the best measure of its frequency,
and should be used in comparative studies.
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Summary Atopic eczema affects 2-3% of the U.K. population. We have carried out a community study in a
semi-rural area to assess its economic impact. One hundred and fifty-five patients with atopic eczema
were identified and expenditure was assessed over a 2-month period. The mean personal cost to the
patient was £25-90. while the mean cost to the health service was £16-20. There were 58 lost
working days and 17 lost school days. A cohort of 10 severely affected patients attending the Royal
Infirmary of Edinburgh were studied; each patient spent, on average, £32 5 in 2 months, and lead to
a mean health service expenditure per patient of £415, in 2 months. If these results were
extrapolated to the U.K. population, the annual personal cost to patients with atopic eczema
would be £29 7m, the cost to the health service would be £12 5m, and the annual cost to society of
lost working days would be £43m, making the total expenditure on atopic eczema £465m.
Medical practice in the U.K. is becoming increasingly
shackled by economic constraints, necessitating a firm
understanding of the financial implications of different
diseases, both to the patient and to the health service.
This is particularly important for the most prevalent
disorders, such as atopic eczema (AE), which affects 1-4
million people in the U.K.1
The economic considerations of AE have received
scant attention, with only one relevant publication in
recent years.2 These authors conservatively estimated
the annual cost of treating children in the U.S.A. to be
$3 64m.2 One objective of the Lothian Atopic Dermatitis
Study was to estimate the costs associated with treating
AE in patients of all ages in the U.K.
Methods
The target population was a semi-rural general practice
of 9786 patients in Livingston, West Lothian. This is
served by eight general practitioners, all of whom use
computerized records that contain diagnostic coding for
various forms of eczema, allowing easy identification of
eczema sufferers known to the practice. The effect of
seasonal variation on the cost of treatment was elimi¬
nated by conducting the study over a 1 year period:
each of the eight GP lists, selected in random order, was
studied over a 6-week period. The sample was chosen in
four stages to identify as many individuals with AE as
possible:
Correspondence: Dr R.M.Herd. Royal Infirmary of Edinburgh NHS
Trust, Level 4—Lauriston Building, Edinburgh EH3 9YW, U.K.
1 Patients with a coding of any type of eczema on the
practice computer were selected and subsequently
examined, together with their families, to confirm the
precise classification.
2 It was apparent that relatively few infants with AE
were registered on the diagnostic index. Therefore, all
families in the practice with a child aged under 2
years were questioned and examined.
3 It was assumed that the diagnostic index on the
practice computer was not comprehensive. To esti¬
mate the number of cases in that section of the
population not included in stages 1 or 2, a random
cluster sample was chosen. Each cluster was a single
family sampled with probability proportional to size.3
Families were contacted by telephone and each adult
family member was interviewed. Adults were ques¬
tioned about their children, and anyone with a
history of an itchy skin was examined.
4 All members of one family in six which had denied
the presence of an itchy member at stage 3 were also
examined, to reduce the chance of cases of AE being
omitted.
Confirmation of the diagnosis of AE was made using
the diagnostic criteria of a U.K. working party.4 Adults
and parents of children who fulfilled these criteria were
asked to record on a proforma, over a 2-month period,
all costs relating to their skin condition (Table 1). These
costs could be attributed either to the patient (e.g.
prescription charges and over-the-counter preparations),
to the health service (e.g. drugs and doctor or nurse
time), or to society (e.g. lost working days). The cost of
20 © 1996 British Association of Dermatologists
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Table 2. Mean annual costs of treating AE in Lothian
1. Keep containers for all creams or ointments, bandages, or tablets
used for your skin which you buy or are prescribed by your doctor.
2. Record dates of all consultations with a doctor or nurse and
expenses involved.
3. Record dates of all visits to hospital and expenses involved.
4. Record all dates off work or school.
5. Record any loss of salary.
6. Record any new clothing or bedding bought as a result of your skin
condition and extra laundry expenses.
7. Record any other expenses incurred directly or indirectly as a result
of your skin condition.






















doctor and nurse time included their salaries and the
general running costs of the hospital or health centre,
and were calculated by standard methods,5 as was the
cost to society of lost working days.6
This was primarily a study of AE in the community,
and only a few patients in the practice had severe
disease. To evaluate the costs of the latter, a cohort of
10 patients, randomly selected over a 1-year period,
with AE severe enough to require attendance at the
Royal Infirmary of Edinburgh (RIE) for dressings or for
in-patient treatment, was assessed in a way similar to
that used in the community study. Patients were
recruited at the time of commencement of dressings or
admittance at the ward, when expenditure was likely to
be at its highest.
The distribution of the data is highly skewed and,
therefore, does not lend itself to parametric statistical
analysis. The aim of this community survey was to
estimate the cost of AE to the whole community and, as
a measure of average, means are an appropriate guide
to community expenditure. In contrast, medians are a
more representative measure of average than means
when outlining the distribution of expenditure in the
target population, and are used where appropriate.
Patients were grouped into three age ranges: 0-2
years, 2-15 years, and over 16 years, and each age
group considered separately. The results were extrapo¬
lated to the whole practice population with the assump¬
tion that the costs of those not identified by the sampling
scheme would be similar to those identified in the
random cluster sample in stage 3.
The chi-squared test with Yates' correction and the
Mann-Whitney U-test were used in the analysis.
Results
One hundred and fifty-five of the 2365 individuals
sampled in the community fulfilled the diagnostic
criteria for AE and were studied in detail: 103 from
sampling stage 1:38 from stage 2; and 14 from stage 3.
Sampling stage 4 produced no further cases. One hun¬
dred and forty-six questionnaires were completed for
the costing assessment: 19 concerned patients less than
2 years, 58 patients aged 2-16 years, and 69 patients
aged 16 years and over. Fifty-eight lost working days
and 17 lost school days were attributable to AE over a
2-month period. A summary of these figures, expressed
per annum, is given in Table 2, and the distribution of
costs to the patient and health service are shown in
Figure 1.
Personal costs
Over 2 months the mean personal expenditure by
patients was £25-90 and the maximum spent by an
individual was £546, 81% of which was due to salary
loss. Ten patients spent over £100 and three spent over
£300. Some patients in remission, and some who were
only mildly affected, had no expenditure attributable to
AE, and this included 45% of those aged less than 16,
compared with 26% of those over 16; i.e. significantly
more of the younger group had no expenditure
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Total spent in 2 months
Figure 1. Expenditure by patients and health service in 2 months.
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was significantly lower than that in the over 16 group
(medians £0-50 and £6-73, P < 0 05), while that in the
under 2 group was significantly lower than the older
age groups, with a ceiling of £40 (median £()•()(),
P < 0 05). The median was £()•()() because over 50%
of parents of the under 2s had no expenditure.
Patients below the age of 16 do not pay for prescrip¬
tions and, of the 69 over 16 years, only 28 spent money
on prescriptions, which accounted for 7% of personal
costs.
Treatments bought over the counter by patients
accounted for 21% of the total cost. These mainly
consisted of emollients, bath additives, shampoos and
evening primrose oil. Very little was spent by adults on
bath additives compared with the younger groups,
while relatively more was spent on shampoos.
There was substantial salary loss but the largest part
of expenditure by patients was on clothing and laundry.
Other expenses consisted of visits to a homeopath by
two children, herbalist advice to one adult, and a visit to
London for Chinese herbal medicine by one child and
his parent.
Health service costs
The mean 2-month cost to the health service was
£16-20 and the maximum attributable to one patient
was £177-07. Ten patients cost the health service over
£50 but only two cost over £100. The median cost in
the 2-15 age group was significantly higher than that
in the over 16 age group (£10-86 and £6-22, P < 0-05)
while that in the under 2 group had a median of
£18-72, significantly higher than the older groups
(P < 0-05).
The majority of health service costs were on treat¬
ments; 38% was on emollients or bath additives, 32%
was on topical steroids, 10% on bandages, while the
remaining 20% was for antihistamines, shampoos,
antibiotics and evening primrose oil.
Eighty-nine percent of prescribed steroids were
moderately potent and mildly potent: 68% of those
prescribed to adults were moderately potent and 69%
prescribed to the younger group were mild.
GP consultations comprised almost 30% of costs
while hospital consultations comprised only 6% of costs.
Hospital cohort
The 2-monthly cost to the health service of the more
severely affected cohort attending hospital was up to
£1500 per patient (mean £415), 63% of which was
incurred by the hospital and 34% by the GPs. The
maximum personal cost was £1225 (mean £325)
over 2 months, 75% of which was due to loss of salary.
Extrapolation to the wider population
The information provided by the sampling scheme
detailed above can be extrapolated to the whole practice
population of approximately 225 patients with AE. The
estimated total annual cost to the health service, and to
the patients in this practice of 9786, would have been
£50,005; 58% would have been incurred by the
patients and 42% by the health service. An estimated
427 working days and 170 school days would have
been lost annually.
Any projection to a wider population is subject to
error but, if these results were representative of the
whole country, they would add up to a total annual
expenditure in the U.K. of £297m by patients. The
estimated annual cost to the health service would be
£12 5m. The cost to society of lost working days would
be £4 3m, resulting in a total cost in the U.K. of £465m,
or a per capita cost of £7-38 per annum.
Discussion
Appraisal of therapeutic cost-effectiveness must become
an essential part of the national allocation of limited
resources, and may be used to identify areas where
savings can be made.fi~8 Furthermore, this knowledge
should demonstrate the value of certain treatments
which might appear to be expensive and inefficient.
Any assessment of costs should include those borne by
the health service, by the sufferers and their families,
and any other costs borne by the rest of society/1
Sufferers from AE, and perhaps other dermatological
disorders, appear to pay a high price for their disease
and, according to our results, a total of £297m is spent
in the U.K. as a result of AE.
Extrapolation of these data to the wider population of
the U.K. should be interpreted cautiously, but the final
estimate of the cost is likely to be an underestimate for
the following reasons:
1 The prevalence of AE in Scotland is less than in the
rest of the U.K.. according to the 1958 National Child
Development Study.9
2 The GPs in the study practice are low prescribers.10
3 None of the patients in the study population had
required hospital treatment during the course of the
study.
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Table 3. Annual per capita cost of treating AE compared with other
medical conditions
U.K. Atopic eczema (this study) £7-38
Venous ulceration11 £6-73
Stroke in Scotland11 £18-78
Benign prostatic hypertrophy12 £l-04-£l-53
4 All patients lived within walking distance of the
health centre, and this minimized travel costs.
5 The cost to society of time spent by carers looking
after dependants is not included.
The data do, however, give some indication of the
magnitude of the problem, with a national cost of
£465m.
Chronic skin diseases differ from most other medical
conditions when their costs are being assessed. A
plethora of over-the-counter preparations is available
for problems ranging from acne to warts. Remedies for
treating dry skin conditions like AE are particularly
numerous, and vary greatly in price. A further drain
on patients' resources comes from the need for new
clothing or bedding, and from the laundry costs which
accounted for 45% of expense to patients in the whole
study, and 63% of the costs to families with children
aged less than 16. One 10-year-old boy, for example,
needed new cotton sheets every 2 months, partly
because of repeated washing, but also because nocturnal
scratching led to extra wear and tear on the sheets.
Patients' readiness to spend large sums of money for
relief from their skin disease is demonstrated by 10
patients in the community paying over £100 in 2 months.
An analysis of the economics ofAE in the U.S.A.2 was
limited for three reasons: it dealt only with children;
treatment in the community was not included; and
costs to the patient were omitted. It would, therefore,
be incorrect to make direct comparisons with our data.
Only a few attempts have been made to quantify the
cost to the health service of medical treatments in the
U.K., and direct comparisons are impossible due to
differences in methodology and in spectrum of disease
(Table 3). The cost of treating venous ulceration which,
in contrast to AE, requires considerable hospital out¬
patient and in-patient time, has been estimated to be
£400m, or £6-73 per head of population, a figure close
to that for AE.U The total annual per capita cost of
treating benign prostatic hypertrophy has been esti¬
mated at £ 1 -04-£ 1 • 5 3.12 The per capita cost of treating
strokes, which usually require prolonged in-patient
therapy, was recently estimated to be £18-78 annually
in Scotland.13 Few would have expected the economic
burden of these conditions so closely to resemble that of
AE.
The financial impact of severe AE has considerable
repercussions on sufferers. Adults with AE have to pay
for prescriptions and are further punished by loss of
salary and high clothing and laundry expenses. We
have shown that an individual attending hospital can
spend as much as £1225 (mean £325) over a 2-month
period which is 12 times that of the average patient in
the community. The financial burden is heavy and the
ceiling of expenditure high.
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Summary An epidemiological study of atopic eczema (AE), based on a semirural community in Scotland, using
sound diagnostic criteria, has yielded prevalence data for all age groups including infants and adults.
The overall 1-year period prevalence, age-standardized to the Scottish population, was 2-3%. The 1-
year period prevalence was highest in the under 2s (9-8%), and showed a continuous reduction with
increasing age. Over the age of 40, AE was found to be relatively rare, with a 1-year period
prevalence of 0-2%. Adults over 16 years made up 38% of all patients with AE.
Atopic eczema (AE) has major socio-economic
implications.1 Although the cellular mechanisms
behind the atopic phenotype have become clearer, and
powerful new treatments have been introduced,2,3 reli¬
able epidemiological data are sparse. The few studies of
prevalence have not always defined their diagnostic
criteria, and some have been based on health visitor
records or questionnaires that have relied on a parental
diagnosis. A variety ofmeasures of frequency have been
used, e.g. cumulative incidence or point prevalence. AE
in infants, and adults, largely has been ignored. The aim
of our study was to estimate, accurately, from a repre¬
sentative population, the prevalence of AE at all ages.
Methods
The study population comprised a semirural general
practice, of 9786 patients, situated in Livingston, a new
town in central Scotland. The age distribution differs
from that in the rest of Scotland, with a larger propor¬
tion of young adults, and a correspondingly smaller
proportion of adults over 65. The social class distribu¬
tion is biased slightly towards social class III, and away
from the higher and lower social classes.4
Howden Health Centre is a well-organized practice,
served by eight general practitioners (GPs). Access to
medical records was facilitated by a computerized
records system. One of us (RMH) examined all available
patients with a coding of eczema on the practice com¬
puter, together with the other members of the family, to
identify those with AE. As infants were poorly repre¬
sented in this sample, every family with a child aged less
than 2 was contacted. To estimate the number of
patients with AE in the remaining practice population
not identified on the computer, a one-stage random
cluster sample of 10% was taken, each cluster being a
family.3
The diagnosis of AE was established using the U.K.
Working Party's diagnostic criteria.6 These require a
history of an itchy skin condition, and three other
criteria, only one of which relies on examination. This
protocol was adhered to strictly. The possible effects of
seasonal variation were eliminated by recruiting
patients over a 1-year period, and by measuring the
1-year period prevalence. Prevalence and standard
errors were calculated by stratified cluster sampling
techniques, with a finite population correction.3
Results
The contact rate was 93% for patients with GP-
diagnosed eczema and their families, 89% for the
under 2s, and 87% for the random cluster sample.
Altogether, 2365 patients were sampled in these
groups, 24% of the practice population.
The U.K. Working Party's diagnostic criteria proved
ideal for use in a community setting. No cases of AE
were thought to be missed. Conversely, two adults who
fulfilled the criteria did not have AE: one had nickel
dermatitis causing eczema on her neck, the other had
pityriasis versicolor. Both were excluded.
The 1-year period prevalences of AE, for the different
age groups, are shown in Table 1, and demonstrate a
steady decline with increasing age. The male:female
18 © 1996 British Association of Dermatologists
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Table 1. One-year period prevalences and standard errors (SE)
1-year period Point prevalence
Age prevalence (SE) of visible eczema
<2 9-8% (0-5) 7-5%
2-11 8-1% (1-5) 2-5%
12-15 2-2% (0-8) 1-1%
16-24 2-1% (0-5) 1-3%
25-40 2-0% (0-7) 0-9%
Over 40 0-2% (0-15) 0-1%
ratio, of 1-5 :1, among infants under 2 (1-year period
prevalence for males, 11-9%, and for females, 7-2%),
was reversed in older age groups (1-year period pre¬
valences aged 2-11, 12-24 and 25+ for males, 7-7,
1-4 and 1-1% respectively, and for females, 11-4, 2-4
and 1-3%). Sixty-five per cent of patients diagnosed as
having AE had active eczema at the time the diagnosis
was made. The overall 1 year period prevalence, age-
standardized to the Scottish population for all age
groups, was 2-3%. Only 52% of patients with AE were
aged between 2 and 15, leaving almost half of AE
patients in the poorly studied groups below the age of
2 and over the age of 16. Thirty-eight per cent of all
patients with AE were over 16. The 1-year period
prevalence in the 16-40 group was 2-0% dropping to
0-2% in the over-forties.
The prevalences of active eczema are also displayed.
While 66% of individuals, aged below 16, were in
remission at the time they were examined, only 47%
of adults over 16 were in remission.
Discussion
The 1-year period prevalence for infants under 2 was
9-8%. The possible reason for the neglect of the epi¬
demiology of AE in infants is that, until now, there have
been no reliable diagnostic criteria. Recent reports have
glossed over the issue of robust inclusion criteria, which
may have contributed to a high lifetime incidence of
20-4%, in the under 3s, in one study/ The U.K. Work¬
ing Party's criteria contribute a framework for compar¬
ison between this and future studies, provided that the
format is adhered to closely.
Information on the prevalence of AE in adults is very
sparse. The figures presented in the Lambeth study,
in 1976, of a prevalence of 12-5% for ages 35-54,
suggest, as acknowledged by the authors, that many
conditions other than AE must have been included
under the banner of 'eczema'.8 There appears to be a
rising prevalence of AE in children9 and. if this shows
a cohort effect, it will be reflected in the adult population,
resulting in a commensurate increase in the proportion
of affected adults. We have shown that the decline in
AE, known to occur with increasing age during child¬
hood and due possibly to age, period or cohort effects,
continues in adult life, until over the age of 40, when AE
becomes relatively uncommon. In one sense this justi¬
fies the almost exclusive attention given to school
children but, when one considers that 38% of all AE
patients are over 16 years of age, the size of the problem
in the adult population becomes apparent. It is clear
from the prevalence figures of active eczema, in Table 1,
that an adult with AE is more likely to have active
disease than a child.
This study is unique in three respects: it uses firm
diagnostic criteria in a community setting, standard
errors are quoted for prevalences, and accurate preva¬
lence figures for adults are given. As AE is a seasonally
influenced disorder, we recommend that the 1-year
period prevalence is the best measure of its frequency,
and should be used in comparative studies.
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